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Abstract 
 
Obesity has been on the rise over the last 30 years, reaching worldwide 
epidemic proportions.  Obesity has been linked to multiple metabolic disorders 
and co-morbidities such as Type 2 Diabetes Mellitus (T2DM), cardiovascular 
disease, non-alcoholic steatohepatitis and various cancers.  Furthermore, obesity 
is associated with a chronic state of low-grade inflammation in adipose tissue 
(AT), and it is thought that insulin resistance (IR) and T2DM is associated with 
the inflammatory state of AT.  
Endothelial cells (ECs) mediate the migration of immune cells into 
underlying tissues during times of inflammation, including obesity- and 
cardiovascular disease-associated inflammation.  Cytokines and 
chemoattractants released from inflamed tissues promote EC activation. Upon 
activation, ECs increase the expression of leukocyte adhesion molecules 
(LCAMs) including intercellular adhesion molecule 1 (ICAM-1), vascular adhesion 
molecule 1 (VCAM-1), E-selectin (E-sel) and P-selectin (P-sel).  Increased 
expression of these LCAMs and increased infiltration of inflammatory cells such 
as macrophages, have been linked to IR, diabetes and atherosclerosis in obese 
individuals.  Preliminary data from our lab suggests that lipolysis induced by the 
β-adrenergic receptor agonist CL 316,243 causes an increase in endothelial 
LCAM gene expression.  In addition, histological analyses show increased 
content of immune cells within AT after the ECs become activated.   
vii 
 
Here, we demonstrate that CL 316,243-induced lipolysis causes infiltration 
of neutrophils in wild type (WT) but not E-sel knockout (KO) mice. Following EC 
activation, there was also a marked increase in cytokine gene expression 
including IL-1β, MCP-1, and TNF-α in an E-sel-dependent manner.  In contrast, 
fasting-induced lipolysis was associated with increased macrophage infiltration 
into AT in the absence of EC activation in an E-sel-independent manner.   
We also examined the role of mitogen activated protein kinase kinase 
kinase kinase 4 (MAP4K4) as a potential contributor to endothelial activation and 
atherosclerosis. Here we demonstrate that deletion of MAP4K4 in ECs in vitro 
diminishes TNF-α-induced EC activation. Additionally, MAP4K4 depletion in 
primary ECs derived from lungs of mice expressing MAP4K4 shRNA decreases 
EC activation. Finally, endothelial specific depletion or loss of MAP4K4 reduced 
atherosclerotic plaque formation in vivo. Taken together, these results highlight 
the importance of the endothelium in modulating obesity-associated co-
morbidities. Furthermore, these data implicate endothelial MAP4K4 as a novel 
regulator of EC activation and consequently AT inflammation and 
atherosclerosis.  
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CHAPTER I:  INTRODUCTION 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER I  2 
 
Obesity and Type 2 Diabetes Mellitus 
 
Obesity has reached epidemic proportions and has increased dramatically 
over the past several decades [1-2].  Obesity has been linked to multiple 
metabolic disorders and co-morbidities such as Type 2 Diabetes Mellitus 
(T2DM), cardiovascular disease, retinopathy, renal failure, as well as 
neurological disorders such as Alzheimer’s disease and various cancers [3-6].  
Current projections for health care costs for the metabolic disorders associated 
with obesity are expected to rise to over 100 billion dollars per year by 2030 [7-8]. 
T2DM is a metabolic disorder that is associated with increased blood 
glucose levels and insulin resistance (IR) in insulin sensitive organs such as 
adipose tissue (AT), liver, and muscle. In obesity, decreased insulin sensitivity in 
peripheral tissues leads to a compensatory increase in insulin production by 
pancreatic β-cells [9-10].  In contrast to Type I diabetes, which results from a lack 
of insulin due to autoimmune destruction of the pancreatic β-cells [11], T2DM is 
marked by an abnormal response to insulin by target tissues.  With chronic 
obesity, many, but not all, patients exhibit IR.  In these patients, the pancreas is 
unable to overcome the increased need for insulin and becomes less reactive to 
increases in plasma glucose levels.  Persistent IR results in β-cell apoptosis, 
decreased insulin secretion, disrupted glucose homeostasis, and T2DM [12-13].  
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Glucose Homeostasis and Insulin Signaling 
 
Plasma glucose levels are often deregulated in obesity.  In healthy 
individuals plasma glucose levels during the day average approximately at 90 
mg/dl.  Control of blood glucose levels after eating and during fasting requires an 
intricate network of regulation involving various organs. Changes in plasma 
glucose levels occur upon food intake or glucose release from the liver as a 
result of glycogenolysis or gluconeogenesis [14-17].   As plasma glucose levels 
fall, the glucagon to insulin ratio increases, halting glucose uptake from plasma.  
Conversely, when plasma glucose levels increase, insulin secretion is stimulated 
and leads to glucose uptake by insulin sensitive organs, such as AT, liver, and 
muscle, and decreased glucose secretion from the liver. Within these insulin 
sensitive tissues, glucose is stored in the form of glycogen, converted to fat, or 
used for energy through glycolysis [12, 18]. 
In adipose and muscle tissues, insulin signaling drives glucose uptake by 
increasing glucose transporter translocation to the plasma membrane. Insulin 
signaling is initiated upon its binding to the insulin receptor. The mature insulin 
receptor consists of two extracellular α subunits and two transmembrane β 
subunits. Binding of insulin to the α subunits leads to a conformational change 
resulting in trans-phosphorylation of one β subunit by the other at multiple 
tyrosine residues. The activated insulin receptor then phosphorylates a variety of 
intracellular substrates including the insulin receptor substrate family (IRS1-5), 
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signal regulatory protein (SIRP) family members, Gab-1, and Cbl. Activated IRS 
proteins interact with and initiate phosphoinositide 3-kinase (PI3K) signaling.  
The consequent activation of Akt2 leads to enhanced transport of Glucose 
Transporter Type 4 (GLUT4) to the plasma membrane [5, 19-20].  GLUT4 is 
required for glucose uptake in both adipose and muscle tissues [21].  
The generation of tissue-specific insulin receptor and GLUT4 knockout 
(KO) mice has contributed greatly to our understanding of IR and diabetes.  
Insulin receptor deficient mice die within a few days after birth, demonstrating the 
critical function of insulin signaling [22-24]. In contrast, tissue specific insulin 
receptor KO mice display milder phenotypes. For example, conditional deletion of 
the insulin receptor in skeletal muscle leads to a decrease in both insulin 
signaling and insulin-dependent glucose transport [25]. However, while these 
mice develop obesity, they do not display systemic IR [25]. This unexpected 
finding is thought to be the result of increased glucose usage by AT and 
compensation by alternative glucose uptake pathways, including Insulin-like 
growth factor 1 receptor (IGF1R) [26-27].  In contrast, muscle specific deletion of 
GLUT4 results in early-onset IR and glucose intolerance [28]. AT specific 
deletion of the insulin receptor shows reduced body fat and serum triglyceride 
(TG) content as well as normal glucose tolerance [29].  Strikingly, however, 
silencing GLUT 4 in AT using an AP2-cre transgene leads to pronounced skeletal 
muscle IR and ultimately diabetes in mice [30].  The differences between insulin 
receptor and GLUT4 tissue specific KO mice demonstrate that disruption of 
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insulin signaling at distinct steps results in differential whole body effects, 
highlighting the complexity of both insulin signaling and tissue crosstalk in 
mediating glucose homeostasis.    
As insulin regulates the release of free fatty acids [31] from AT into the 
circulation, decreased insulin levels and peripheral IR increases both lipolysis 
and FFA release into the circulation. This, in turn, results in enhanced lipid 
deposition within muscle and liver, exacerbating IR [5, 32-34]. Indeed, reports 
indicate that obese individuals have increased lipid deposition in both muscle and 
liver [35-36].  Furthermore, lipid metabolite accumulation, such as diacylglycerols 
(DAGs) and ceramides, may impair insulin action, through a decrease in glucose 
uptake by muscle, leading to hyperglycemia, worsening IR and eventually 
resulting in T2DM [4, 37-38] or increased glucose output by liver [39].  
Interestingly, hepatic IR has been observed within three days of being on a high 
fat diet (HFD), prior to the development of obesity, and has been associated with 
increased levels of lipid signaling species such as ceramides and DAGs [40-41].   
Other studies, however, have questioned the hypothesis that obesity increases 
AT lipolysis, citing a reduction in plasma FFAs when normalized per unit of 
adipose mass in obese individuals [42-43] and a reduced activation of the 
lipolytic pathway in obesity [44-45].  While it is still unclear whether lipolysis 
increases during obesity, it is becoming evident that adipocyte dysfunction during 
obesity leads to an increase in ectopic lipid deposition and IR. 
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Adipose Tissue Function 
 
 Although glucose homeostasis requires a complex network of interactions 
among various organs, it is now clear that AT is a key regulator of whole body 
glucose homeostasis [46-48].  AT is a dynamic tissue that is composed of 
multiple cell types including adipocytes, immune cells, and vascular cells such as 
endothelial cells (ECs) [49-50].  AT has two main functions: one is to perform 
lipogenesis and store excess energy from nutrients in the form of concentrated 
TGs and the second is to undergo lipolysis to release energy on demand in the 
form of FFA and glycerol [51-56].  The ability of white AT (WAT) to sequester 
excess nutrients as TGs acts to preserve whole body glucose homeostasis by 
sparing other tissues from ectopic lipid deposition [34].  Moreover, AT also 
secretes a variety of hormones and cytokines (known as adipokines) that 
modulate feeding behaviors, energy metabolism, and insulin sensitivity [57-61].  
Insulin resistant AT is associated with enhanced lipolysis, reduced TG 
sequestration, and increased immune cell accumulation [33, 62-63].  Therefore, it 
is hypothesized that obesity induced AT dysfunction is a critical factor in the 
development of T2DM.   
TG esterifcation occurs when insulin stimulates an increase in liproprotein 
lipase (LPL) levels and activity.  LPL, which is found on the luminal side of ECs, 
then hydrolyses plasma TGs from circulating lipoproteins into glycerol and FFAs, 
allowing adipocytes to take up and store FFAs [55-56, 64].  The process of 
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lipolysis acts to hydrolyze TGs from adipocyte intracellular lipid droplets into 
FFAs and glycerol for subsequent utilization [65].  Three lipases, adipose 
triglyceride lipase (ATGL), hormone-sensitive lipase (HSL), and 
monoacylglycerol lipase (MGL) are activated and catalyze the breakdown of TGs 
into FFAs and glycerol.  ATGL and HSL are responsible for 90% of all lipolysis [5, 
51, 66].  ATGL breaks down TGs into DAGs and requires interaction with 
coactivator comperative gene identification-58 (CGI-58) to completely hydrolyze 
TGs. HSL predominantly breaks down DAGs into monoacylglycerols (MG). Upon 
phoshporylation, HSL gains access to lipid droplets via Perilipin-1 to fully 
hydrolyze TGs into FFAs and glycerol.   
β3-adrenergic stimulation is required for stimulation of lipolysis via the 
protein kinase A (PKA) pathway.  Following neural/catecholamine stimulation of 
the β3-adrenergic receptor, adenylyl cyclase is activatied to increase cyclic 
adenosine monophosphate (cAMP), which binds to and activates cAMP-
dependent PKA.  PKA further phosphorylates HSL and the lipid droplet protein 
Perilipin-1, leading to TG hydrolysis [67-69].  TG hydrolysis allows for stored 
lipids to be used as fuel by other tissues during fasting [51].  
β3-adrenergic receptor agonists mimic the endogenous stimuli of lipolysis 
by activating adenylyl cyclase and downstream PKA signaling, which culminates 
in the phosphorylation of both HSL and Perilipin-1 [67-70].  Therefore, activation 
of β3-adrenergic receptors leads to increased levels of glycerol and FFAs in the 
circulation. β3-adrenergic receptors belong to the G-protein coupled receptor 
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family and are predominantly found in AT [71].  The β1-adrenergic receptor is 
predominantly expressed in the heart, and the β2-adrenergic receptor is 
expressed in the heart, kidneys, lungs, and blood vessels [72].  Stimulation of β3-
adrenergic receptors has anti-obesity effects and causes remodeling of WAT [71, 
73-76].  Some of the major changes induced by β3-adrenergic receptor agonists 
involve an increase in metabolic rate, FA oxidation, and mitochondrial biogenesis 
[77-79].   
In mice and humans, acute treatment with CL 316,243, a β3-adrenergic 
receptor agonist, increases blood FFA levels, energy expenditure, and insulin 
levels while reducing food intake by 45% [71, 80].  We and others have found 
that, similar to fasting-induced lipolysis, chemical induction of lipolysis in lean, 
insulin-sensitive animals by CL 316,243 administration induces an immune 
response in the AT, as marked by an increase in inflammatory cell infiltration [81-
82]. Intraperitoneal injection of wild type (WT) [73] mice with CL 316,243 leads to 
a rise in FFA and glycerol levels in the blood [63, 83].  This lipolytic effect is 
followed by an increase in chemoattractant activity and macrophage 
accumulation in AT.  
Although this CL 316,243 treatment is associated with improved insulin 
sensitivity, insulin resistant AT is also associated with enhanced lipolysis, 
reduced TG sequestration and increased immune cell accumulation [33, 62-63, 
76]. 
CHAPTER I  9 
 
Therefore, it is not clear whether or not AT immune cell infiltration leads to an 
improvement in AT function and whole body insulin sensitivity.  It is possible that 
immune cells secrete both beneficial and deleterious factors.  
 
Obesity and Inflammation 
 
Dysfunctional obese AT is associated with increased infiltration [63, 84] 
and/or proliferation of immune cells [62].  While acute inflammation represents a 
rapid, focused immune response to infection or injured tissues, obesity-
associated inflammation is moderate and persistent [85].  It has been 
hypothesized that macrophages are recruited into AT as a result of increased 
adipocyte cell death, which is caused by hypoxia and excessive adipocyte 
expansion upon increased nutrient intake [86-88].  Alternatively, macrophages 
may be recruited into obese AT in order to buffer the excess release of lipids 
found during an increased lipolytic state, and to remodel the AT following 
adipocyte cell death [50, 62-63].  Hence, it remains unclear whether leukocyte 
infiltration into AT causes the deleterious effects associated with metabolic 
disorder or whether leukocytes play a protective role in obesity-associated 
disorders.  There is emerging evidence that certain leukocytes, such as 
eosinophils, seem to have a protective metabolic effect [89], while other 
leukocytes, such as macrophages, cause metabolic deregulation [33, 90].    
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The first link between obesity and inflammation was the observation of 
increased levels of tumor necrosis factor (TNF)-α in the AT of obese mice [91]. A 
multitude of studies have since demonstrated that additional inflammatory 
cytokines including interleukin (IL)-6, interleukin-1 beta (IL-1β), and monocyte 
chemotactic protein-1 (MCP-1) are increased in obese AT [92-93]. Furthermore, 
it is now appreciated that other tissues, including the liver, pancreas, and even 
the brain, exhibit increased inflammatory cytokine expression and inflammation in 
obesity [91, 94-96].  
There seems to be a switch from anti-inflammatory immune cells within 
lean individuals to a more pro-inflammatory profile of immune cells in obese 
individuals [97-98].  The AT of mice fed a HFD displays increased inflammatory 
macrophage infiltration when compared with AT of chow-fed lean mice [99-100].  
Furthermore, obese IR patients exhibit increased AT pro-inflammatory 
macrophage accumulation compared to obese insulin sensitive individuals [101].  
This increase in macrophage content may further contribute to the increased pro-
inflammatory cytokine expression in obese AT. Similarly, other immune cells 
such as B cells, natural killer T (NKT) cells, mast cells, and neutrophils are also 
found in greater numbers in obese AT [97, 102-103].  Furthermore, recent 
studies suggest that there is an increase in CD8+ T cells [104] and a decrease in 
regulatory T (Treg) cells within obese AT [31, 105]. Finally, obese human tissues 
also demonstrate increased inflammatory cytokine production, inflammatory 
kinase activation, and immune cell infiltration [106-109].   
CHAPTER I  11 
 
Chronic obesity-associated AT inflammation may act to disrupt normal 
metabolic homeostasis and impair insulin action. Altered inflammatory signaling 
in obese AT can lead to adipocyte IR. Indeed, adipocytes display decreased 
insulin action such as reduced glucose uptake following TNF-α treatment [110-
112]. In addition, inflammatory kinases can disrupt metabolic function by either 
inhibiting insulin signal transduction or promoting continued unrestrained 
inflammation. First, inflammatory kinases such as Inhibitor of κB kinase (IKK) or 
c-Jun N-terminal kinase (JNK) can inhibit IRS-1 activation and stability, to reduce 
insulin signaling and its metabolic actions [113].  Second, these kinases can 
mediate transcriptional programs through activation of downstream transcription 
factors including nuclear factor κB (NF-κB) or activator protein -1 (AP-1). This 
can lead to increased pro-inflammatory cytokine production, which in turn can 
contribute to dampened insulin signaling. However, recent reports suggest that 
the role of inflammatory kinase activation in obese AT may not be as clear as 
once thought.  Indeed, adipocyte-specific IKKβ KO mice show an unexpected 
increase in AT inflammation as well as impaired glucose tolerance [114].  These 
new data illustrates that IKK not only has pro-inflammatory functions within the 
NF-κB pathway but also has an anti-inflammatory role through its regulation of IL-
13 [114]. In another study, specifically promoting AT inflammation impaired 
adipose remodeling, promoted ectopic lipid deposition and induced glucose 
intolerance [115]. Therefore, the precise role of these inflammatory signaling 
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cascades in modulating AT physiology and whole body glucose homeostasis 
remains unclear.   
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Figure 1.1 Obesity-associated inflammation in adipose tissue.  In healthy 
lean individuals, adipocytes store free fatty acids as triglycerides, which are 
hydrolyzed during fasting.  As the balance between nutrient intake and energy 
expenditure increases, adipocytes hypertrophy to accommodate the increase in 
triglyceride input.  This compensation allows for an individual to maintain an 
insulin sensitive state.  However, during chronic caloric intake, adipocytes are no 
longer able to enlarge to accommodate the increase in nutrient intake.  Hence, 
adipocytes begin to secrete pro-inflammatory adipokines leading to the infiltration 
of immune cells, such as macrophages.  These immune cells also secrete pro-
inflammatory factors, creating an inflammatory state.  In obesity-induced 
inflammation, the increase in the number of immune cells within adipose tissue is 
associated with ectopic lipid deposition and insulin resistance. 
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The Role of Inflammatory Signals in Obesity 
 
Although increased AT inflammation correlates with IR, it is now 
appreciated that inflammation is not always deleterious and instead may be 
beneficial by facilitating tissue remodeling [50]. In fact, the effects of obesity-
associated inflammation may change during the course of obesity.  For instance, 
reducing AT inflammation early in obesity, at 3 days post-HFD feeding has no 
effect upon insulin sensitivity.  However, reducing AT inflammation in established 
obesity improves glucose homeostasis [116].  
Some critical inflammatory signaling molecules/pathways that have been 
implicated in promoting AT dysfunction and IR are discussed in detail below: 
 
TNF-α  
TNF-α is a potent pro-inflammatory cytokine that plays an important role in 
immunity, proliferation, and apoptosis [117-118]. TNF-α is mainly produced by 
monocytes and macrophages; however, it can also be produced by various other 
cell types including T and B lymphocytes, NKT cells, adipocytes, and ECs [118-
124]. TNF-α is synthesized as a ~26kDa transmembrane precursor form that 
undergoes processing by metalloproteases to be released as a ~17kDa soluble 
form [125]. Both transmembrane and soluble TNF-α are active and have distinct 
signaling outputs [118].  
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Cellular responses to TNF-α are initiated upon ligand binding to two 
structurally distinct receptors: tumor necrosis factor receptor type I (TNF-RI) and 
tumor necrosis factor receptor type II (TNF-RII) [126-128]. Both receptors are 
transmembrane glycoproteins that share homology within their N-terminal 
extracellular domains, which contain multiple cysteine-rich repeats [129]. 
However, there is considerable variation in their intracellular domains, which 
accounts for distinct intracellular signaling [130-131]. Furthermore, the receptors 
differ in their expression pattern and in their binding affinities to TNF-α ligands 
[132-133].  
TNF-RI mediates most of the pro-inflammatory and apoptotic pathways 
induced by TNF-α. In adipocytes, TNF-RI-mediated signaling inhibits the insulin 
signaling pathway [134-135] and increases lipolysis in adipocytes [136-137]. 
However, as both receptors can be processed and secreted as soluble forms 
[138], which inhibit TNF-α signaling, they may both play important regulatory 
functions by modulating TNF-α activity in obesity. Furthermore, the cellular 
response to TNF-α may also depend on crosstalk between the two receptors 
[139].  
As previously mentioned, TNF-α was the first inflammatory marker 
demonstrated to modulate IR [91].  TNF-α downregulates the expression of 
various components of the insulin signaling pathway including IRS-1, GLUT4, 
peroxisome proliferator activated receptor gamma (PPARγ), and adiponectin 
[110, 140-142].  In addition, TNF-α also enhances leptin production, leading to 
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reduced pancreatic insulin secretion and increased IR [143].  Furthermore, TNF-
α deficient mice are protected from IR when placed on a HFD [144].  Finally, 
TNF-α stimulates MCP-1 production, further enhancing macrophage recruitment 
into AT [145].  These combined effects can contribute to increased obesity-
associated AT inflammation and promote IR. 
 
NF-κB  
The NF-κB signaling pathway plays a critical role in inflammation by 
regulating the expression of cytokines, chemokines, and leukocyte adhesion 
molecules (LCAMs) on ECs [146].  NF-κB activation occurs in response to 
receptors associated with pathogen associated molecular patterns (PAMP)s, 
damage associated molecular patterns (DAMP)s, and pro-inflammatory cytokines 
such as TNF-α, IL-1, and IL-6 [147-149]. NF-κB refers to transcription factors of 
the Rel family of DNA-binding proteins, which recognize a common sequence 
motif. In the absence of an activating signal, NF-κB dimers are sequestered in 
the cytosol [150]. A family of inhibitory proteins, IκBs, prevent NF-κB 
translocation into the nucleus by binding to and masking the NF-κB nuclear 
localization signal [151-152]. Upon stimulation, IκB proteins are rapidly 
phosphorylated by the kinase IKK [153]. Both catalytic subunits, IKKα and IKKβ, 
can phosphorylate IκB [154-155], and the phosphorylation sites serve as 
recognition sites for an SCF-type E3 ubiquitin ligase, E3RSIκB/β-TrCP [156]. The 
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subsequent ubiquitination of IκB targets it for proteolytic degradation [157-159]. 
This results in the release of NF-κB dimers from IκB-mediated sequestration, 
allowing it to translocate into the nucleus and mediate target gene transcription 
[160-161].  
NF-κB signaling regulates the expression of numerous genes, such as 
TNF-α and interferon γ (IFNγ), which are involved in inflammation, innate 
immunity, cell survival, and tissue homeostasis [162-163]. One reported 
mechanism by which activation of the NF-κB pathway promotes IR is through 
inhibitory phosphorylation of IRS-1 [113].  Furthermore, overexpression of IKKβ 
in hepatocytes leads to both a local and systemic increase in pro-inflammatory 
gene expression and results in system IR in the absence of obesity [114].  In 
addition, increased circulating FFAs in obesity has been reported to activate NF-
κB through Toll like receptor 4 (TLR4) signaling, which impairs insulin signaling in 
muscle tissue [164]. Accordingly, TLR4 KO mice have been reported to display 
increased insulin sensitivity on a HFD compared with WT controls [164]. 
However, the role NF-κB plays in regulating inflammation in different cell types 
has recently been brought into question.  Adipocyte specific IKKβ-deficient mice 
were shown to exhibit a somewhat counterintuitive effect, with deletion of  IKKβ 
worsening IR and enhancing AT inflammation [114].  However, this study 
illustrated that IKKβ is involved in the regulation of anti-inflammatory IL-13 
expression, hence accounting for the worsening IR and AT inflammation seen in 
mice deficient in IKKβ [114].  
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MCP-1/CCL2 
 
 MCP-1, also known as chemokine (C-C motif) ligand 2 (CCL2),  is the first 
discovered member of the C-C chemokine family, and this family of chemokines 
is characterized by four highly conserved cysteine residues that form stabilizing 
intramolecular disulfide bridges [165].  The main receptor for MCP-1 is C-C 
chemokine receptor type 2 (CCR2), which is present in two isoforms, CCR2A 
and CCR2B [166]. These isoforms are generated by alternative splicing from the 
same gene and have distinct C-terminal tails [166]. The major sources of MCP-1 
production are monocytes and macrophages. However, it is also produced by a 
broad spectrum of cells including ECs, adipocytes, smooth muscle cells and 
fibroblasts [145, 167-168]. MCP-1 gene expression is regulated by various 
factors, including insulin, TNF-α, IL-1β and lipopolysaccharide (LPS), via 
activation of NF-κB, p38 MAPK and/or early growth response protein 1(EGR1) 
signaling [169-172]. 
 The main function of MCP-1 is to recruit circulating monocytes, 
predominantly Ly6chi, to sites of inflammation. Therefore, it plays a critical role in 
potentiating obesity-associated inflammation.  Insulin induces a significant 
increase in secretion of MCP-1 from IR adipocytes both in vitro and in vivo [171].  
The expression of both MCP-1 and CCR2 are significantly increased in the 
subcutaneous and visceral AT (VAT) of obese individuals [168]. Additionally, 
circulating plasma levels of MCP-1 are significantly higher in obese individuals 
CHAPTER I  19 
 
and in patients with T2DM [173-178]. Furthermore, CCR2- deficient mice are 
protected against visceral fat deposition and IR when placed on a HFD [179]. 
MCP-1 has also been shown to further promote AT inflammation by promoting 
macrophage proliferation in obese AT [62].  However, although increased levels 
of MCP-1 correlate with IR, the role of MCP-1 in regulating insulin sensitivity 
remains unclear due to divergent metabolic phenotypes of HFD-fed MCP-1 KO 
mice [62, 84, 180].  A possible explanation for these conflicting findings may be 
due to differences in experimental procedures, including variations in genetic 
backgrounds of mice as well as the diet provided to the mice.  Also, there could 
be compensation by the actions of other ligands for CCR2, as several ligands 
exist for CCR2 other than CCL2/MCP-1 [62, 84, 180-182].  
 
MAPK/JNK/p38 MAPK 
  
Mitogen-activated protein kinases (MAPKs) are activated by a variety of 
extracellular stimuli including growth factors, environmental stresses, and 
inflammatory cytokines. The diversity of these stimuli translates into a broad 
range of cellular responses such as proliferation, differentiation, and migration. 
Two members of the MAPK family of signaling proteins, JNK and p38 MAPK, are 
stress activated protein kinases and play prominent roles in inflammation [183-
184]. Both JNK and p38 MAPK are activated by upstream MAPK kinases 
(MKKs). Dual phosphorylation within the activation loop of JNK is mediated by 
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the cooperative action of two MKKs (MAP2K4 and MAP2K7), whereas p38 
MAPK is phosphorylated by MAP2K4, as well as MAP2K3 and MAP2K6 [183, 
185-188]. These MKKs are themselves dually phosphorylated by a variety of 
MKK kinases (MAP3Ks), and likewise these kinases are phosphorylated by 
MAP3K kinases (MAP4Ks).   Activated JNK phosphorylates various substrates 
including the c-Jun component of the transcription factor AP-1, which prevents 
the proteolytic degradation of c-Jun, and therefore increases transcriptional 
output of AP-1-containing complexes [189].  
Numerous studies have demonstrated a link between JNK activity, insulin 
signaling and obesity. In cultured adipocytes, JNK can directly inhibit insulin 
signaling by phosphorylating IRS-1 on Ser307 and reducing insulin sensitivity 
[190-191].  However, while in vitro phosphorylation of IRS-1 is associated with 
IR, there is evidence that phosphorylation of IRS-1 in vivo has insulin sensitizing 
effects [192].  Furthermore, mice fed a HFD display increased JNK1 activity in 
AT, liver, and muscle. Similarly, leptin deficient ob/ob mice display increased 
JNK1 activity. In contrast, JNK1 deficient mice have improved insulin signaling 
and sensitivity when fed a HFD [193]. Macrophage specific deletion of JNK 
results in insulin sensitivity and a decrease in AT inflammation in mice placed on 
a HFD compared to WT controls [194].  Muscle specific JNK1 deficient mice 
displayed more insulin sensitivity when placed on a HFD compared to WT 
controls [195].  However, JNK1 deletion in hepatocytes has the opposite effect, 
causing more glucose intolerance, IR and even hepatic steatosis [196].  Hence, 
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JNK signaling seems to have tissue specific functions. Nevertheless, JNK seems 
to contribute to obesity-associated inflammation by regulating the expression and 
activation of many inflammatory mediators, including LCAMs [189].  
 
MAP4K4 
 
 
 
Our laboratory identified a mitogen activated protein kinase kinase kinase 
kinase 4 (MAP4K4) in an RNAi-based screen designed to uncover novel 
regulators of adipocyte function [197].  We showed that MAP4K4 is a negative 
regulator of adipocyte function, as silencing MAP4K4 enchanced insulin-sensitive 
deoxyglucose uptake in cultured adipocytes via increased expression of PPARγ 
and GLUT4 [197].  In addition, siRNA-mediated silencing of MAP4K4 partially 
protected against TNF-α mediated reduction of PPARγ and GLUT4 expression 
[197].  
MAP4K4 is a serine/threonine kinase and belongs to a group of kinases 
related to Saccharomyces cerevisiae Sterile 20 (STE20) [198-199].  In mammals, 
these kinases can be subdivided into two structurally distinct families: the p-21 
activated kinases (PAKs) and the germinal center kinases (GCKs), which 
includes MAP4K4. While the structure of the kinase domain is conserved among 
the two groups, it is located in the C-termini of the PAKs and in the N-termini of 
GCKs.  In addition, the PAKs, but not the GCKs, contain an N-terminal GTP 
binding domain. Finally, MAP4K4 contains a C-terminal regulatory domain.  
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Numerous studies have identified a multitude of roles for MAP4K4, which include 
promoting proliferation, motility, and IR [197, 200-204].  
MAP4K4 was also identified in a yeast two-hybrid screen for proteins that 
interact with the SH3 domain of Nck, which is an adaptor protein that is involved 
in growth factor signaling [205]. Therefore, MAP4K4 is also referred to as NIK - 
Nck Interacting Kinase [205].  In this study, transient overexpression of MAP4K4 
in 293T cells resulted in activation of the JNK pathway via activation of Mitogen-
activated protein kinase kinase kinase 1 (MEKK1). MAP4K4-mediated JNK 
activation was also enhanced upon MAP4K4 interaction with Rap2 (a Ras family 
small GTP-binding protein) [206]. Studies in D. melanogaster revealed that the 
MAP4K4 homolog Misshapen (Msn) acted upstream of JNK signaling to regulate 
cell differentiation and proliferation [206-210].   
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Figure 1.2 Schematic representation of MAP4K4.  MAP4K4 is a 
serine/threonine kinase that is related to the STE20 family of kinases.  This 
diagram illustrates the motifs in mouse MAP4K4.  Within the MAP4K4 sequence 
there is the N-terminal catalytic domain, the coiled-coil region, the Nck-binding 
motif and the C-terminal Citron homology domain.  The MAP4K4 motifs that 
interact with the SH3 domain of Nck, an adaptor protein involved in growth factor 
signaling, are also shown.  
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Although some studies have suggested that MAP4K4 is an upstream 
activator of the JNK1/2, extracellular signal-related kinase 1/2 (ERK1/2) and p38 
MAPK pathways [202, 211-213], our laboratory has recently shown that this may 
not be the case as increased expression of MAP4K4 does not activate JNK 
[201].  In addition, MAP4K4 depletion in cultured adipocytes did not affect TNF-α 
mediated induction of JNK1/2 phosphorylation [201].  Signaling through TNF-RI, 
but not TNF-R2, caused a sustained JNK1/2 and p38 MAPK phosphorylation and 
resulted in enhanced MAP4K4 expression in cultured adipocytes [214].  
Furthermore, in cultured myotubes MAPKs were not required to mediate the 
effects of MAP4K4, where genes for skeletal muscle differentiation were 
increased [204].  Notably, MAP4K4 deficient mice are embryonic lethal and 
display severe defects in mesodermal differentiation.  Taken together, these 
studies suggest that MAP4K4 may function through a variety of signaling 
pathways in addition to the JNK signaling pathway [215]. 
Incidentally, a recent study identified a link between MAP4K4 and the 
Hippo signaling pathway [216]. In Drosophila enteroblasts, Msn activate Warts, 
the homolog of LATS and this interaction is conserved in mammals [216].  
Whether the interaction between MAP4K4 and LATS is functionally relevant in 
other contexts, such as in obesity and inflammation, has yet to be determined.   
In addition to its role in adipocytes, MAP4K4 has important functions in 
other cell types.  In macrophages, in vitro depletion of MAP4K4 decreased LPS-
stimulated TNF-α expression, and macrophage-specific silencing of MAP4K4 in 
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vivo inhibited TNF-α expression and prolonged survival of mice to LPS-challenge 
[203].  Furthermore, MAP4K4 has been shown to induce IR in cultured human 
myocytes through the TNF-α signaling pathway [202].  These studies 
demonstrate the variety of cells within which MAP4K4 plays a key role during 
inflammatory states.  Despite these data, endogenous activators of MAP4K4 
remain unknown.   
 
Endothelial Cells and Inflammation 
 
ECs regulate vascular tone and serve as a selective barrier between the 
circulation and all tissues [217].  As the regulators of vascular homeostasis, ECs 
interact with circulating cells in plasma as well as the underlying smooth muscle 
cells.  The development of ECs requires a complex interaction between vascular 
endothelial growth factor (VEGF) as well as growth factors from the angiopoietin 
and ephrin families.  Although VEGF initiates vascular formation, angiopoietins 
and ephrins are required for the maturation, integration, patterning, and 
maintenance of ECs within the mature vessel [81, 218-219].  
During inflammation, ECs permit inflammatory cells to enter underlying 
tissues [220].  ECs are bound to one another via adhesive structures such as 
tight junctions, adherens junctions or gap junctions, depending on the tissue 
[221-222].  Tight junctions seal ECs to one another with the aid of occludins, 
which are transmembrane proteins that interact with cytosolic proteins [81, 223-
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224].  Adherens junctions are connected with cadherins, such as VE-cadherin, 
that bind to cytoplasmic actin microfilaments [225].  During inflammation, the 
opening of these junctions mediates vascular permeability.  The adhesive 
proteins rearrange and allow the passage of plasma proteins and potentially 
circulating immune cells into underlying tissue [81]. 
Vascular permeability during inflammation is coordinated by interactions 
between cytokines, leukocytes and ECs [81, 226].  ECs are the key players in 
coordinating the recruitment and extravasation of immune cells to injured sites.  
ECs not only react to cytokines that are released by other cells, but they also 
synthesize and secrete cytokines and chemokines [81, 227-228]. Indeed, TNF-α 
or IL-1β treatment promotes the release of cytokines, such as TNF-α itself, from 
ECs [81, 229-231]. 
The cycle of cytokine response and release creates a more robust pro-
inflammatory state within ECs [81]. Genes that regulate cytokine and chemokine 
production are regulated through several transcription factors including AP-1, 
signal transducer and activator of transcription (STATs) and NF-κB [81, 232].  
Furthermore, this pro-inflammatory state also enhances the expression of 
LCAMs, which are required for the attachment and transmigration of immune 
cells across ECs into underlying tissue [233]. 
It is hypothesized that EC dysfunction contributes to the obesity-
associated chronic inflammation by promoting infiltration of immune cells into AT 
and IR [234-236].  The release of cytokines, such as MCP-1 and TNF-α, from AT 
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activates ECs to allow for the transmigration of immune cells from circulation into 
the underlying AT.  When activated, ECs increase the expression of LCAMs such 
as intercellular adhesion molecule 1 (ICAM-1), vascular adhesion molecule 1 
(VCAM-1), E-selectin (SELE) and P-selectin (Selp, expressed in rodents but not 
humans) [237-239]. Increased expression of ICAM-1, VCAM-1, SELE, and Selp 
is associated with obesity [238, 240].  Interestingly, high levels of insulin have 
been shown to activate ECs and act synergistically with inflammatory cytokines 
such as TNF-α and LPS [241].  Increased expression of LCAMs allows for rolling 
and adhesion of leukocytes along the endothelium in preparation for migration 
through the endothelium into underlying tissue [217].   
The diminished rolling of leukocytes in blood is achieved by the binding of 
leukocytes to the selectin proteins, which are transmembrane glycoprotein 
adhesive molecules present on both immune cells and ECs [242-244].  E-selectin 
(E-sel) is expressed by ECs, while P-selectin (P-sel) is found on ECs and 
platelets [245].  E-sel is not constitutively expressed but is induced during 
inflammation, while P-sel is constitutively expressed and its expression 
increases.  The slowing of leukocyte rolling via selectin-mediated interactions 
enables immune cells to sense and react to inflammatory stimuli. In response to 
EC cytokines, immune cells adhere more firmly to the endothelium and prepare 
for transmigration [81].  Once leukocytes have adhered to the endothelium, 
integrin ligands such as ICAM-1 and VCAM-1, aid in the transmigration across 
the endothelium [246-247].  Leukocytes, such as neutrophils and macrophages, 
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pass through the EC junctions when VE-cadherin-catenin complexes are 
interrupted [247-249].  
Recent studies have demonstrated the importance of P-sel-mediated 
interactions in modulating obesity-associated inflammation. P-selectin 
glycoprotein ligand-1 (Psgl-1) is the primary ligand for leukocyte binding of Sele 
and Selp in rodents.   Obese mice lacking Psgl-1 are protected against 
inflammation in VAT [239, 250].  In addition, Psgl-1 deficient mice fed a HFD 
display a reduction in both macrophage infiltration and inflammatory gene 
expression including MCP-1 [250].  These mice are also more insulin sensitive 
compared to WT controls on a HFD, an effect that is independent of changes in 
body weight [250]. 
The role of E-sel in inflammation has been extensively studied [82, 233, 
251]. E- and P-sel are functionally redundant in various contexts [251], making it 
difficult to ascertain specific functions.  E-sel deficient mice display decreased 
neutrophil migration during inflammation compared to WT mice, only when P-sel 
is also blocked with the use of an antibody [252].  A specific role for E-sel was 
identified in venules of TNF-α treated mice. In this context, E-sel deficient mice 
displayed increased leukocyte rolling [251].  Therefore, by reducing rolling, E-sel 
may facilitate leukocyte infiltration into inflamed tissues. To date, the specific 
contribution of E-sel to obesity-associated inflammation had not been examined.  
Here we suggest that E-sel is required for lipolysis- and HFD-induced 
inflammation, which will be discussed in detail in Chapters II and III.  
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Atherosclerosis 
 
Obesity promotes a host of vascular dysfunctions, which affect not only 
the endothelium within AT but also throughout the whole body.  Specifically, 
obesity is associated with atherosclerosis, a leading cause of death worldwide.  
Atherosclerosis cases have increased along with increased obesity rates.  The 
development of atherosclerosis leads to cardiovascular disease culminating in 
myocardial infarcts, ischemia, and stroke [253-254].  Similar to the inflammatory 
state associated with T2DM, atherosclerosis is caused by long term recruitment 
and activation of immune cells in the arteries [254].  This inflammation is initiated 
in part by increased levels of circulating low-density lipoproteins (LDLs), which 
are responsible for carrying lipid molecules through circulation.  They contain 
cholesterol particles, TGs, and phospholipids with a single apolipoprotein B 
(ApoB).  When ApoB contacts the vessel intima, the lipid content of the LDL is 
exposed and oxidized [253].  Oxidized lipoproteins induce inflammation, resulting 
in cytokine secretion and EC activation [253].  LCAM upregulation allows for 
monocytes to transmigrate from circulation into the sub-endothelial space.  
These monocytes accumulate within the tunica intima, differentiate into 
macrophages and phagocytose oxidized LDL.  Foam cells, lipid-laden 
macrophages that have taken up LDL with high amounts of cholesterol and TGs 
[255], accumulate within vessels during obesity-associated nutrient overload.  
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Subsequently, these foam cells undergo apoptosis and release their contents 
into the surrounding tissue [255].  
In addition, the abundance of LDL particles within the circulation induces 
macrophages to release cytokines, thus attracting more monocytes to the 
affected area and leading to a chronic inflammatory state [256].  Foam cells, 
combined with calcium and fibrous connective tissue, make up the atheromas 
found in atherosclerosis.  Furthermore, the initiation and progression of the 
atherosclerotic plaques has been linked to LCAM upregulation, particularly that of 
VCAM-1 [257-260]. LCAM expression is upregulated by JNK and NF-κB 
signaling pathways [217].  Reducing endothelial-specific NF-κB signaling, 
through the expression of dominant negative IκBα in ECs or removal of 
NEMO/IKKγ, dampened LCAM expression and atherosclerosis progression in 
Apolipoprotein E (ApoE) deficient mice on a high cholesterol diet [146]. 
In atherosclerosis, as the atheroma hardens, the reduced flexibility of 
vessels increases the risk of plaque rupture.  In addition, atheromas can obstruct 
blood flow, leading to the serious complications associated with cardiovascular 
disease such as ischemia and stroke [253, 261].   The study of atherosclerosis 
has been aided by ApoE deficient mice [262-263].  ApoE is a glycoprotein that 
contributes to the formation of all lipoproteins with the exception of LDL [264].  It 
acts as a ligand for low density lipoprotein receptor (LDLR), very low density 
lipoprotein receptor (VLDLR) and low density liproprotein related protein 1 
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(LRP1).  Chylomicrons and intermediate density lipoprotein particles (IDL) are 
removed from blood via the interaction between ApoE and these receptors [265].   
ApoE is expressed in multiple cell types including hepatocytes, 
adipocytes, and macrophages.  In adipocytes, ApoE expression is negatively 
regulated by TNF-α and positively regulated by PPARγ agonists [266]. When 
transferred into WT mice, ApoE-/- adipocytes do not display hypertrophy on a 
HFD [267].  In the absence of ApoE, there is decreased expression and transport 
of VLDLR, LDLR and LRP1 within adipocytes, which results in reduced TG 
uptake [268]. This effect, combined with reduced ectopic lipid deposition, results 
in leaner and more insulin sensitive mice [265, 269].  Furthermore, when ApoE-/- 
mice are crossed with ob/ob mice, a genetic model of obesity, they are still 
protected from IR and obesity [270-272].     
Although ApoE-/- mice are more insulin sensitive, they also have high 
levels of circulating cholesterol and TGs [262-263].  Therefore, they develop 
severe atherosclerosis. However, ApoE deficient mice are protected from stroke 
and infarcts as the atheromas do not break apart to obstruct vessels [273]. These 
mice provide an excellent model in which to identify and characterize in vivo 
regulators of atherosclerosis. 
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Specific Aims 
 
My current study focuses on understanding the connection between 
inflammation and AT dysfunction.  Specifically, I examined the contribution of EC 
activation to the progression of obesity-associated diseases.  I hypothesize that 
ECs may play an essential function in leukocyte recruitment into obese AT 
because ECs regulate leukocyte rolling and extravasation [62, 83, 90].  In 
Chapters II and III, I present data to suggest that E-sel activation and regulation 
is required for lipolysis- and HFD-induced inflammation.  In addition, I 
endeavored to identify a novel regulator of EC activation in the context of 
inflammation.  In Chapter III, I explore the role of MAP4K4 in obesity-associated 
atherosclerosis.  
 
 The aims of this thesis are to: 
1. determine the role of ECs in mediating obese AT inflammation 
and atherosclerosis 
2. examine the function of endothelial MAP4K4 in atherosclerosis  
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Abstract 
 
Obesity-associated AT inflammation has been suggested to cause IR, but 
weight loss and lipolysis also promotes AT immune responses. In acute 
inflammation local vascular ECs become activated to mediate leukocyte rolling, 
adhesion, and extravasation by up-regulation of LCAMs such as E-sel and P-sel. 
In obesity, leukocyte-endothelial interactions are required for inflammation of AT; 
however, it is not known whether lipolysis-induced inflammation requires 
activation of ECs. Here, we show that β3-adrenergic receptor stimulation by CL 
316,243 promotes AT neutrophil infiltration in WT and P-sel-null mice but not in 
E-sel-null mice. Increased expression of AT cytokines IL-1β, IL-6, CCL2, and 
TNF-α in response to CL 316,243 administration is also dependent upon E-sel 
but not P-sel. In contrast, fasting increases adipose-resident macrophages but 
not neutrophils and does not activate adipose-resident endothelium. Thus, two 
models of lipolysis-induced inflammation induce distinct immune cell populations 
within AT and exhibit distinct dependence on endothelial activation. Importantly, 
our results indicate that β3-adrenergic stimulation-induced lipolysis leads to up-
regulation of E-sel in AT ECs to induce neutrophil infiltration.  
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Introduction 
AT is a dynamic organ that responds to nutritional cues by synthesizing 
and storing excess energy in the form of TGs during times of abundance or 
releasing energy in times of need. Lipolysis, the hydrolysis of adipocyte TG to 
glycerol and fatty acids, occurs in response to β-adrenergic stimulation by 
catecholamines during fasting. Conversely, in the fed state, lipolysis is inhibited 
by insulin, which stimulates lipogenesis [1]. Lipolysis is controlled in adipocytes 
by three main lipases, ATGL, HSL, and MGL [2-5]. Stimulation of β-adrenergic 
receptors activates adenylyl cyclase, which increases cAMP and activates 
cAMP-dependent PKA. PKA phosphorylates the coactivator for ATGL, CGI-58 in 
addition to HSL and the lipid droplet protein perilipin, thus enhancing TG 
hydrolysis [6-8]. This process allows the stored lipid within the adipocyte to be 
used by other tissues during times of reduced nutrients for such processes as 
beta-oxidation and adaptive thermogenesis [1-2].  
AT homeostasis is maintained in a complex manner through interactions 
with adipocytes, ECs, immune cells, and others. In obesity, IR may cause an 
increase in basal lipolysis associated with an immune response in AT. Such AT 
inflammation is thought to promote systemic glucose intolerance [1]. Previous 
studies have suggested that a similar adipose inflammatory response occurs 
during weight loss or fasting, states that are also associated with increased AT 
lipolysis, as a consequence of β-adrenergic stimulation [9, 10]. However, these 
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latter conditions are not associated with glucose intolerance and IR, raising an 
interesting paradox.  
It is appreciated that inflammatory responses require vascular EC 
activation, which increases expression of LCAM that are necessary for leukocyte 
extravasation from the vasculature to areas of inflammation [11, 12]. ECs can 
become activated in response to lipid stimuli, and this activation model is 
accepted in the context of atherosclerosis development [13]; however, the role 
that adipose-resident ECs play in recruitment of leukocytes to AT upon lipolysis 
is not well understood. Some studies suggest that endothelial-leukocyte 
interactions are required for AT inflammation [14-16]; however, whether these 
interactions are mediated by AT lipolysis is not known.  
Here, two model systems of lipolysis induction were utilized; systemic 
treatment with the β3-adrenergic receptor agonist CL 316,243 or fasting to 
determine the role of adipose-resident EC function in the AT immune response 
that ensued. Although fasting increased macrophage accumulation within AT, we 
surprisingly found that chemical induction of lipolysis caused a robust neutrophil 
infiltration into AT. Although fasting did not activate ECs, β3-adrenergic receptor 
activation-mediated lipolysis robustly increased expression of endothelial LCAMs 
ICAM-1, E-sel, and P-sel in adipose-resident endothelium. Furthermore, E-sel 
was required to mediate the β3-adrenergic receptor activation-induced AT 
immune response. Thus, β3-adrenergic receptor-activated lipolysis, but not 
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fasting-induced lipolysis, is associated with an immune response in AT that 
correlates with and is mediated by EC activation.  
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Experimental Procedures 
Animals 
Wild type C57Bl/6J animals, B6.129S4-Seletm1Dmil/J and B6.129S7-
Selptm1Bay/J animals were purchased from Jackson Laboratories. E-sel and P-sel 
KO animals were maintained by homo- and heterozygote breeding at the 
UMASS animal facility. Male animals were used between 8–12 weeks of age for 
all of the studies. Mice were injected with 0.5 or 1 mg/kg CL 316,243 (Santa Cruz 
Biotechnology) or PBS intraperitoneally for the indicated times. Fasting studies 
were performed after acclimation of the mice to paper bedding for at least 5 days. 
Mice were fasted for 24 h. Mice were placed on a HFD for 8, 12 and 16 weeks. 
For glucose tolerance tests (GTTs), mice were injected with 1g/kg of glucose 
intraperitoneally, and blood glucose measurements were taken at 15, 30, 45, 60, 
90, and 120 min post injection.  Mice on a HFD were sacrificed after 17-18 weeks 
on HFD prior to FACS analysis, mRNA quantification, plasma insulin and 
myeloperoxidase (MPO) level measurements. The University of Massachusetts 
Medical School Institutional Animal Care and Use Committee approved all of the 
animal procedures.  
Cell Culture 
Human umbilical vein endothelial cell (HUVEC)s (Clonetics) were 
maintained in EGM-2 media (Lonza) at 37 °C and 5% CO2. Cells were treated 
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with PBS, the indicated amounts of CL 316,243, or 10 ng/ml tumor necrosis 
factor (TNF)-α (Calbiochem) for 6 h.  
RNA Isolation and Quantitative RT-PCR 
Total RNA was isolated from whole epididymal AT or HUVECs following 
the manufacturer's protocol (TriPure, Roche). Precipitated RNA was treated with 
DNase (DNA-free, Invitrogen) prior to reverse transcription (iScript Reverse 
transcriptase, Bio-Rad). SYBR green quantitative PCR (iQ SYBR green 
supermix, Bio-Rad) was performed on the Bio-Rad CFX97. Mice were injected 
for 30 min, 2 h, 4 h, 6 h, 16 h, or 24 h as indicated. The data obtained from the 
CL 316,243-injected mice were normalized to that from the PBS-injected mice at 
each time point to control for injection-induced inflammation. Primer sequences 
are as follows: Itgam: 5′-ATGGACGCTGATGGCAATACC-3′, 3′-
TCCCCATTCACGTCTCCCA-5′; CD68: 5′-CCATCCTTCACGATGACACCT-3′, 
3′- GGCAGGGTTATGAGTGACAGTT-5′; Itgax: 5′-
CTGGATAGCCTTTCTTCTGCTG-3′, 3′-GCACACTGTGTCCGAACTCA-5′; 
EMR1: 5′-CCCCAGTGTCCTTACAGAGTG-3′, 3′-GTGCCCAGAGTGGATGTCT-
5′; IL1β: 5′-GCAACTGTTCCTGAACTCAACT-3′, 3′-
ATCTTTTGGGGTCCGTCAACT-5′; CCL2: 5′-
TTAAAAACCTGGATCGGAACCAA-3′, 3′-GCATTAGCTTCAGATTTACGGGT-5′; 
TNFα: 5′-CAGGCGGTGCCTATGTCTC-3′, 3′-CGATCACCCCGAAGTTCAGTAG-
5′; IL-6: 5′-TAGTCCTTCCTACCCCAATTTCC-3′, 3′-
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TTGGTCCTTAGCCACTCCTTC-5′; ICAM-1: 5′-
GTGATGCTCAGGTATCCATCCA-3′, 3′-CACAGTTCTCAAAGCACAGCG-5′; 
VCAM-1: 5′-AGTTGGGGATTCGGTTGTTCT-3′, 3′-
CCCCTCATTCCTTACCACCC-5′; Sele: 5′-ATGAAGCCAGTGCATACTGTC-3′, 
3′-CGGTGAATGTTTCAGATTGGAGT-5′; Selp: 5′-
CATCTGGTTCAGTGCTTTGATCT-3′, 3′-ACCCGTGAGTTATTCCATGAGT-5′; 
36B4: 5′-TCCAGGCTTTGGGCATCA-3′, 3′-
CTTTATCAGCTGCACATCACTCAGA-5′; ICAM-1 (human): 5′-
TCTGTGTCCCCCTCAAAAGTC-3′, 3′-GGGGTCTCTATGCCCAACAA-5′; 
VCAM-1 (human): 5′-ATGCCTGGGAAGATGGTCG-3′, 3′-
GACGGAGTCACCAATCTGAGC-5′ Sele (human): 5′-
GATGAGAGGTGCAGCAAGAAG-3′, 3′-CTCACACTTGAGTCCACTGAAG-5′; 
RPLP0: 5′-CAGATTGGCTACCCAACTGTT-3′, 3′-
GGGAAGGTGTAATCCGTCTCC-5′.  
Histology 
Epididymal AT was fixed in 10% formalin, paraffin embedded, and stained 
with hematoxylin and eosin (H&E). Photos were taken with an Axiovert 35 Zeiss 
microscope (Zeiss, Germany) equipped with an Axiocam CCl camera at 50× or 
100× magnification.  
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Non-esterified Fatty Acid (NEFA) Measurements 
EDTA plasma was collected from the retro-orbital sinus after isoflurane 
anesthesia. NEFA were measured with a colorimetric assay (Wako) using the 
manual procedure according to the manufacturer's instructions.  
Flow Cytometry 
The epididymal AT stromal vascular fraction (SVF) was isolated by 
digestion in Hanks balanced salt solution, 2.5% BSA and 2 mg/ml collagenase 
for 45 min and strained through a 70 μm filter followed by red blood cell lysis. 
Cells were blocked with mouse IgG in FACS buffer (1% BSA/PBS). Cells were 
stained with antibodies directed toward F4/80 (APC, ABd serotec), CD11b (Percp 
5.5, BD), Siglec F (PE, BD), GR-1 (APC-Cy7, BD), Ly6c (PE-Cy7, BD), Galectin 
3 (FITC, BioLegend), and CD11c (V450, BD). The data were collected on an 
LSRII (BD) and were analyzed with FlowJo software. Samples were gated for 
scatter and single cells. Gates were drawn based on fluorescence minus one 
(FMO) controls. A total of 50,000-100,000 events were recorded.  
Insulin and myeloperoxidase (MPO) measurements 
Mice were subjected to isoflurane anesthesia, and EDTA plasma was 
collected from the retro-orbital sinus followed by VAT extraction. Insulin and Mpo 
levels were measured with an Elisa assay (Millipore and Abcam, respectively) 
according to the manufacturer's instructions.  
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Results 
β-Adrenergic Stimulation in Vivo Induces Adipose Tissue Inflammation 
To study the effects of lipolysis on epididymal AT inflammation, we utilized 
a β3-adrenergic receptor agonist that has been previously documented to 
robustly induce lipolysis and hence, AT inflammation, CL 316,243 (CL) [9, 10, 17, 
18]. 8–12-week old lean male C57Bl/6J mice were injected intraperitoneally once 
with PBS or 0.5 mg/kg CL 316,243 and plasma and whole epididymal AT were 
isolated after 30 min or 2, 4, 6, 16, and 24 h of treatment. As expected, CL 
316,243 treatment acutely increased serum non-esterified fatty acids (NEFA) by 
a maximum of 4-fold at the 30-min time point (Fig. 2.1A). AT samples from these 
same mice were obtained for histology, and the slides were stained with H&E. As 
expected, an increase in AT inflammatory cells was observed in the CL 316,243-
treated mice compared with the PBS-treated mice that peaked between 16 and 
24 h after treatment (Fig. 2.1B).  
To identify what cell types were infiltrating into the epididymal AT upon CL 
316,243 treatment, we isolated the AT SVF from animals that had been injected 
with PBS or 1 mg/kg CL 316,243 for 18 h and characterized these cells with flow 
cytometry. Macrophages were identified as cells that were positive for CD11b 
and F4/80 antigen and negative for the eosinophil marker Siglec F [19, 20]. In the 
PBS-treated mice, ∼12% of Siglec F-negative SVF cells were positive for both 
CD11b and F4/80. Interestingly, no increase in these CD11b & F4/80 double 
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positive cells after CL 316,243 treatment was observed, as was previously 
reported (Fig. 2.1C) [9]. However, there was a 65% increase in CD11b-positive 
cells after CL 316,243 treatment (39% in PBS-treated mice versus 64% in CL 
316,243-treated mice), which was statistically significant (p < 0.005, data not 
shown) (Fig. 2.1C).  
Multiple types of immune cells are present within AT [19, 21-26]. In an 
acute immune response, neutrophil infiltration precedes that of monocytes and 
macrophages [27]. Thus, we hypothesized that these CD11b-positive cells that 
had infiltrated into the CL 316,243-treated AT may be of the granulocyte lineage. 
To assess this, the cells were stained for GR-1, a granulocyte marker that is 
present on neutrophils. CL 316,243 treatment increased GR-1-positive cells in 
AT SVF nearly 10-fold over PBS injection alone (Fig. 2.1C). These GR-1-positive 
cells highly expressed CD11b and did not express high levels of F4/80 or Ly6c 
(Fig. 2.1D), indicating that they are likely neutrophils rather than myeloid-derived 
suppressor cells [28]. Thus, CL 316,243 administration intraperitoneally is 
associated with acute AT inflammation and neutrophil infiltration.  
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Figure 2.1 CL 316,243 administration induces lipolysis and neutrophil 
accumulation in adipose tissue. Mice were injected with 0.5 mg/kg CL316,243 
or PBS intraperitoneally, and AT was harvested 30 min to 24 h later as indicated. 
A, plasma was drawn from the retroorbital sinus and NEFA were measured (n = 
3, *; p < 0.05). B, VAT was isolated, fixed in 10% formalin, embedded in paraffin, 
and stained with H&E. Slides are representative of 3–6 animals at 100× 
magnification. 
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Figure 2.1 Continued. CL 316,243 administration induces lipolysis and 
neutrophil accumulation in adipose tissue. C, mice were injected with 1 
mg/kg CL 316,243 or PBS. After 18 h, AT SVF was isolated and FACS analysis 
was performed. Upper panels, PBS-treated animals. Lower panels, CL-treated 
animals. Left panels, Siglec F-negative, CD11b- and F4/80-positive cells. Right 
panels, GR-1-positive cells. Panels are representative of 6–11 animals per 
group. D, GR-1 positive cells (from 1C, lower right panel) were stained 
additionally for CD11b (left), Ly6c and F4/80 (right). Panels are representative of 
6–11 animals per group.              
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Increased Expression of Cytokines, but Not Macrophage Marker Genes, in  
Adipose Tissue after CL 316,243 Treatment 
To further characterize the nature of this immune response, RNA was 
isolated from mice that had been injected intraperitoneally with PBS or 0.5 mg/kg 
CL 316,243 after 0.5, 2, 4, 6, 16, or 24 h, and the expression of several 
inflammatory genes was measured by qRT-PCR. Gene expression was 
normalized to 36B4, and the gene expression in the CL 316,243-treated AT was 
compared with that in the PBS-treated mice for each time point. Because CL 
316,243 treatment is associated with increased AT inflammation, macrophage 
marker genes as well as the expression of several inflammatory cytokines were 
measured. Consistent with the 65% increase in CD11b-positive cells by FACS 
(data not shown and Fig. 1C) after CL 316,243 treatment, a 3.47-fold increase in 
Itgam, which encodes CD11b, was noted 24 h after CL 316,243 treatment (Fig. 
2.2A). A gradual increase in the mRNA levels of an additional leukocyte marker, 
CD68 was also observed, which peaked at a 2-fold increase in the CL 316,243-
treated mice after 24 h (Fig. 2.2B).  
Although it has been previously documented that CL 316,243 treatment 
causes AT macrophage infiltration [9, 10], no change in Itgax mRNA levels, 
which encodes CD11c protein, could be detected during the CL 316,243 
treatment time course (Fig. 2.2C).  Furthermore, an acute 50% reduction in 
EMR1 expression (Fig. 2.2D), which encodes the macrophage F4/80 protein, 
was observed after CL 316,243 treatment compared with PBS-treated mice.  
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Although, Cd68 marker gene expression was increased at 24 hours after CL 
316,243 injection, all other macrophage gene expression markers were reduced 
post-CL 316,243 injection when compared to PBS controls.  These results are 
consistent with the notion that the CL 316,243-induced infiltrating cells are not 
macrophages.  
Large increases were also noted in the mRNA levels of several 
inflammatory cytokines within AT acutely after CL 316,243 treatment. IL-1β 
mRNA levels were increased by 140-fold and CCL-2/MCP-1 mRNA levels were 
increased by 30-fold in CL 316,243-treated compared with PBS-treated AT. The 
expression levels of these cytokines peaked 4 h after CL 316,243 treatment, and 
remained increased for at least 24 h (Fig. 2.2 E, F).  
Cytokines TNF-α and IL-6 were also induced in AT by CL 316,243 
treatment, by 6- and 600-fold, respectively (Fig. 2.2 G, H). The expression of 
these cytokines peaked two hours after CL 316,243 treatment and also remained 
elevated over 24 h. Interestingly, the up-regulation of these cytokines within the 
AT occurred at a time point that was prior to leukocyte infiltration, according to 
histology of H&E stained AT sections (Fig. 2.1B), which suggests that these 
cytokines may be secreted from adipose-resident cells rather than infiltrating 
cells. Thus, the up-regulation of these cytokines may be important for induction of 
leukocyte infiltration into AT in response to β3-adrenergic receptor activation.  
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Figure 2.2 Temporal regulation of inflammatory cell gene expression by CL 
316,243. Mice were injected with 0.5 mg/kg CL 316,243 or PBS intraperitoneally 
for 30 min to 24 h as indicated. Visceral adipose tissue was isolated, RNA was 
extracted and quantitative RT-PCR was performed for A, Itgam (CD11b), B, 
CD68, C, Itgax (CD11c), D, EMR1 (F4/80). Data represent average gene 
expression as compared with 36b4 ± S.E. (n = 3–7, *; p < 0.05). 
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Figure 2.2 Continued. Temporal regulation of inflammatory cell gene 
expression by CL 316,243. Mice were injected with 0.5 mg/kg CL 316,243 or 
PBS intraperitoneally for 30 min to 24 h as indicated. VAT was isolated, RNA 
was extracted and quantitative RT-PCR was performed for E, Il1β, F, CCL2 
(MCP-1), G, TNFα, and H, IL-6. Data represent average gene expression as 
compared with 36b4 ± S.E. (n = 3–7, *; p < 0.05). 
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β3-Adrenergic Stimulation Does Not Up-regulate Leukocyte Adhesion 
Molecules in Endothelial Cells in Vitro  
We hypothesized that the immune cells that were infiltrating AT after CL 
316,243 treatment derived from the circulation, and if this were the case, that 
these immune cells were being recruited to the AT through activation of adipose-
resident endothelium. Inflammatory stimuli cause transcriptional up-regulation of 
endothelial genes ICAM-1, VCAM-1, E-sel, and P-sel, and this up-regulation is 
necessary for leukocyte recruitment into the inflamed tissue [11, 29]. Indeed, CL 
316,243-treated mice displayed an increase in the mRNA expression of these 
genes compared with PBS-treated mice. In the CL 316,243-treated mice, there 
was a 3-fold increase in ICAM-1 expression, a 17-fold increase in E-sel 
expression, and a 4.5-fold increase in P-sel expression that peaked 4 h after CL 
316,243 treatment (Fig. 2.3 A-D). This peak in the expression of these LCAM 
genes preceded the immune cell infiltration into AT (Fig. 2.1), suggesting that up-
regulation of these molecules may be necessary for lipolysis-induced leukocyte 
infiltration. However, VCAM-1 expression was not induced after CL 316,243 
treatment (Fig. 3B). As VCAM-1 is important for firm adhesion of 
monocytes/macrophages and T cells to the vessel wall, rather than neutrophils 
[12], it is not surprising that this adhesion molecule was not up-regulated, as 
macrophages were not the primary AT infiltrating cell type (Figs. 2.1, 2.2).   
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To test whether ECs could be directly activated by CL 316,243 in the 
absence of other cell types, primary endothelial cells derived from HUVECs were 
treated with increasing doses of CL 316,243 for 6 h, at which time RNA was 
extracted and qRT-PCR was performed for ICAM-1, VCAM-1, and E-sel. 
Importantly, no up-regulation of the adhesion molecules was noted after CL 
316,243 treatment at doses that are comparable to the in vivo dose employed 
(0.1–1 μg/ml), and only at the highest dose of CL 316,243 treatment (100 μg/ml) 
was a very small up-regulation of ICAM-1 expression noted. In contrast, 
stimulation of HUVECs with TNF-α, a known activator of ECs, caused significant 
up-regulation of ICAM-1, VCAM-1, and E sel (Fig. 2.3E). We also performed 
similar experiments in which HUVECs were treated with 1 μg/ml CL 316,243 in 
combination with 100 μM palmitate or oleate for 4 h, and we found that these 
fatty acids were not sufficient to up-regulate LCAM expression in the presence or 
absence of CL 316,243 (data not shown). These results suggest that CL 316,243 
treatment itself causes little or no EC activation, but suggest that other adipose-
resident cells activate the ECs in a paracrine manner.  
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Figure 2.3 Endothelial cell activation by β3-adrenergic stimulation of 
adipose tissue in vivo, but not in vitro CL 316,243 treatment. Mice were 
injected with 0.5 mg/kg CL 316,243 or PBS intraperitoneally for 30 min to 24 h as 
indicated. VAT was isolated, mRNA was extracted, and qRT-PCR was performed 
for A, Icam-1, B, Vcam-1, C, Sele (E-selectin), and D, Selp (P-selectin). Data 
represent average gene expression as compared with 36b4 ± S.E. (n = 3–10, *; p 
< 0.05).                            
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Figure 2.3 Continued.  Endothelial cell activation by β3-adrenergic 
stimulation of adipose tissue in vivo, but not in vitro CL 316,243 treatment. 
E, HUVEC were treated for 6 h with various doses of CL316,243 or 10 ng/ml 
TNFα. mRNA was extracted and qRT-PCR was performed for ICAM-1, VCAM-1, 
and SELE (E-selectin). Data represent average gene expression as compared 
with RPLP0 ± S.E. (n = 3–5, *; p < 0.05, **; p < 0.005). 
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Differences between Fasting-induced and CL 316,243-induced Adipose 
Tissue Inflammation 
The results obtained after CL 316,243 injection suggested that the AT 
lipolysis that ensues upon β3-adrenergic stimulation causes AT inflammation and 
EC activation. To test this hypothesis, we extended our study to a different 
physiological system that would also increase adipocyte lipolysis. Recent studies 
have suggested that extended fasting increases AT macrophage infiltration 
because of enhanced lipolysis [9, 30]; therefore, we subjected lean 8–12 week 
old C57BL/6J mice to a 24-h fast, isolated plasma, and assessed NEFA levels as 
an indication of lipolysis. As expected, a 3-fold increase in plasma NEFA was 
observed in the fasted animals compared with those that had been ad lib fed 
(Fig. 2.4A). Furthermore, plasma NEFA levels in the fasted animals were 
comparable to those seen in the mice 30 min after injection with 0.5 mg/kg CL 
316,243 (Fig. 2.1A).  
Next, mRNA was extracted from VAT of the fed and fasted animals, and 
qRT-PCR was performed for the same inflammatory genes measured after CL 
316,243 treatment (Figs. 2.2, 2.3). Surprisingly, no correlation of gene expression 
between CL 316,243-induced inflammation and fasting-induced inflammation 
was observed. Though significant up-regulation of ICAM-1 and E sel after CL 
316,243 treatment was noted, no up-regulation of either of these genes in AT 
after fasting (Fig. 4B) could be detected. Furthermore, though we had observed 
several-fold increases in TNF-α, IL1β, CCL-2, and IL-6 after CL 316,243 
CHAPTER II 72 
 
treatment (Fig. 2.2 E-H), fasting actually induced a significant reduction in TNF-α, 
IL1β, and CCL-2 mRNA levels (Fig. 2.4B), consistent with a previous report [30].  
Finally, we assessed what types of cells were infiltrating AT after fasting. 
Mice were fasted for 24 h, SVF was isolated from the epididymal AT and flow 
cytometry was performed. In contrast to CL 316,243 treatment, a 50% increase 
(15% to 22%, p = 0.002) in macrophage cells that were Siglec F negative, CD11b 
and F4/80 positive was observed in fasted animals. Furthermore, fasting did not 
induce a GR1-positive cell population (Fig. 2.4D). The infiltrated cells in both ad 
lib fed and fasted animals expressed high levels of Ly6c and Galectin 3 and did 
not express CD11c (Fig. 2.4, E-F), suggesting that this cell population is an M2-
like “anti-inflammatory” cell population [23] and is similar to the type of 
macrophages that normally reside in lean AT, which is consistent with a previous 
report [30]. Therefore, although fasting and CL 316,243 treatment each induce 
AT lipolysis, and thus, plasma NEFA levels to a similar extent (Figs. 1A, 4A), 
these two model systems induce different AT phenotypes. CL 316,243 treatment 
induces a more inflammatory, neutrophil-mediated infiltration, whereas fasting 
reduces inflammatory cytokine expression while increasing M2-type 
macrophages in AT.  It is also important to consider the fact that our study did not 
measure lipolysis-induced changes in glycerol levels in plasma via 
hyperinsulinemic-euglycemic clamps.  Plasma glycerol measurement may be a 
more accurate way of assessing lipolysis induced through either fasting or CL 
316,243 treatment. 
CHAPTER II 73 
 
 
Figure 2.4 Fasting-induced lipolysis causes macrophage infiltration and 
reduces cytokine expression in adipose tissue. Mice were fed ad libidum or 
fasted as indicated. A, plasma was drawn from the retroorbital sinus and NEFA 
were measured (n = 6, #; p < 0.0005). B, VAT was isolated, RNA was extracted, 
and quantitative RT-PCR was performed for the indicated genes. Data represent 
average gene expression as compared with 36b4 ± S.E. (n = 6–7, *; p < 0.05, **; 
p < 0.005). 
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Figure 2.4 Continued. Fasting-induced lipolysis causes macrophage 
infiltration and reduces cytokine expression in adipose tissue. C–F, AT SVF 
was isolated and FACS analysis was performed. C, ad lib fed animals. D, fasted 
animals. Left panels, Siglec F-negative, CD11b- and F4/80-positive cells (p < 
0.005). Right panels, GR-1-positive cells. Panels are representative of 9–11 
animals per group. E and F, CD11b, F4/80-positive cells from C-D were stained 
additionally for Galectin 3, Ly6c, and CD11c. E, ad lib fed animals. F, fasted 
animals. Left, Galectin 3, Ly6c-positive cells. Right, CD11b, CD11c-positive cells. 
Panels are representative of 9–11 animals per group. 
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E-selectin Is Required for β3-Adrenergic Receptor-mediated Inflammation  
E- and P-sel are required for leukocyte recruitment to sites of inflammation 
in animal models, and are necessary for neutrophil rolling along vessels within 
inflamed tissue. It has also been demonstrated that E- and P-sel have redundant 
and unique functions [12, 31-34]. E-sel expression is low until it is 
transcriptionally up-regulated in response to stimuli. Conversely, P-sel is not as 
transcriptionally regulated, and is stored preformed in Weibel-Palade bodies 
within the EC [11]. We hypothesized that because neutrophil infiltration was 
associated with CL 316,243-mediated inflammation, and E-sel was the LCAM 
that was most highly induced by CL 316,243 treatment in AT, that E-sel would be 
required for CL 316,243-induced AT inflammation. However, though it was not 
transcriptionally up-regulated to the same extent as E-sel, we could not exclude 
the possibility that P-sel may also be important for CL 316,243-induced 
neutrophil recruitment to AT. Conversely, because none of the LCAMs were 
induced by fasting, and neutrophil infiltration was not associated with fasting-
induced inflammation, we hypothesized that neither E- nor P-sel would be 
required for fasting-induced inflammation.  
To test this hypothesis, we utilized mice lacking E-sel (E-sel KO) or P-sel 
(P-sel KO), which have been extensively described [31-33, 35]. These mice were 
injected with 0.5 mg/kg CL 316,243 or PBS, and plasma was collected for NEFA 
analysis. Importantly, 30 min following injection of 0.5 mg/kg CL 316,243, NEFA 
levels were increased 4–5 fold in the plasma of E-sel and P-sel KO mice, similar 
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to WT animals (Fig. 2.5A), suggesting that β3-adrenergic receptor stimulation-
mediated lipolysis occurs normally in these animals.  
Because maximal leukocyte infiltration of AT is between 16–24 h after CL 
316,243 injection, tissues were isolated from these animals 18 h post-injection. 
VAT was excised from the injected mice and histological sections were prepared 
and stained with H&E. No obvious histological changes in the AT from either 
genotype that had been injected with PBS were detected. As expected, 
enhanced immune cell infiltration in WT animals was observed. In P-sel KO mice, 
AT inflammation was induced to a similar extent as in the WT mice (Fig. 2.5B). 
However, the E-sel KO mice were remarkably protected from the leukocyte 
infiltration that ensued upon CL 316,243 injection, thus suggesting that E-sel is 
required for β3-adrenergic receptor-induced neutrophil infiltration (Fig. 2.5B), as 
indicated by histological analysis.  
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Figure 2.5 E-selectin KO mice are protected from CL 316,243-mediated 
adipose tissue immune cell infiltration. WT, E-sel KO, or P-sel KO mice were 
injected with 0.5 mg/kg CL 316,243 or PBS intraperitoneally for 30 min to 24 h as 
indicated. A, plasma was drawn from the retroorbital sinus and NEFA were 
measured (n = 3 - 7, **; p < 0.005). 
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Figure 2.5 Continued. E-selectin KO mice are protected from CL 316,243-
mediated adipose tissue immune cell infiltration. WT, E-sel KO, or P-sel KO 
mice were injected with 0.5 mg/kg CL 316,243 or PBS intraperitoneally for 30 min 
to 24 h as indicated. B, VAT was isolated, fixed in 10% formalin, embedded in 
paraffin, and stained with H&E. Slides are representative of 3–6 animals at 50× 
magnification. 
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We next determined whether E-sel was also required for CL 316,243-
induced inflammatory gene expression in VAT. To assess this, mRNA was 
extracted from VAT 18 h after injection with PBS or 0.5 mg/kg CL 316,243, and 
real time qRT-PCR was performed on several inflammatory genes. EMR1 
(F4/80) mRNA levels exhibited no increase after CL 316,243 treatment in any of 
the genotypes, which correlates with the notion that the infiltrating cells in this 
model are not macrophages. However, there was a 60% increase in Itgam 
(CD11b) expression in WT animals after CL 316,243 treatment that was not seen 
in the E-sel KO animals. CL 316,243 injection increased CD68 expression in WT 
and P-sel KO mice by 88% and 2-fold, respectively. However, E-sel KO mice 
were refractory to this increase and also displayed a significant reduction in 
CD68 expression after CL 316,243 injection compared with P-sel KO animals 
(Fig. 2.6A).  
Inflammatory cytokine expression was induced (CCL-2, 7-fold; IL1β, 9-
fold; TNF-α, 2-fold; and IL-6, 19-fold) after CL 316,243 treatment in WT mice, 
with equivalent or enhanced induction of these genes in P-sel KO mice. 
However, E-sel KO mice were completely protected from the increased AT 
inflammatory cytokine response that ensued after CL 316,243 injection. 
Furthermore, significant reductions in CCL-2, IL1β, and TNF-α were seen in CL 
316,243-injected E-sel KO mice compared with WT mice (Fig. 6A).  
Finally, we evaluated whether E-sel KO mice were protected from 
neutrophil infiltration that ensued after CL 316,243 injection. To test this 
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hypothesis, WT and E-sel KO mice were injected with 1 mg/kg CL 316,243, and 
VAT was isolated 18 h later to obtain the SVF for FACS analysis. Though a 5-
fold, significant increase was noted in GR1-positive cells in WT animals after CL 
316,243 injection, no significant increase in GR1-positive cells was found in E-sel 
KO mice (Fig. 2.6 B-D).  These data suggest that E-sel, but not P-sel, is required 
for the AT inflammation that ensues upon β3-adrenergic receptor stimulation, 
which is mediated by neutrophil recruitment. This is in contrast to fasting-induced 
AT inflammation, which is mediated by macrophages. 
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Figure 2.6 E-selectin KO mice are protected from CL 316,243-mediated 
adipose tissue inflammation. A, WT, E-sel KO, or P-sel KO mice were injected 
with 0.5 mg/kg CL 316,243 or PBS intraperitoneally for 18 h. VAT was isolated, 
mRNA was extracted, and qRT-PCR was performed for the indicated genes. 
Data represent average gene expression as compared with 36b4 ± S.E. (n = 3–9, 
*; p < 0.05, **; p < 0.005). 
 
 
CHAPTER II 82 
 
 
Figure 2.6 Continued. E-selectin KO mice are protected from CL 316,243-
mediated adipose tissue inflammation. B–D, WT or E-sel KO mice were 
injected with 1 mg/kg CL 316,243 or PBS for 18 h. AT SVF was isolated and 
FACS analysis was performed. B, WT mice. C, E-sel KO mice. Upper panels, 
PBS-treated animals. Lower panels, CL 316,243-treated animals. Left panels, 
Siglec F-negative, CD11b and F4/80-positive cells. Right panels, GR-1-positive 
cells. Panels are representative of 5–14 animals per group. D, quantitation of B-
C. Left panel, Siglec F-negative, CD11b and F4/80-positive cells. Right panel, 
GR-1-positive cells. (n = 5–14, +; p = 0.06, #; p < 0.0005).    
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Glucose Homeostasis Is Not Altered in E-selectin KO Mice compared to WT 
Mice on a HFD 
 
 We observed that E-sel is required for lipolysis-induced AT infiltration of 
immune cells. Therefore, we examined whether glucose tolerance and insulin 
sensitivity are affected by EC activation. WT and E-sel KO mice were placed on 
a HFD, and GTTs were conducted at 8, 12, and 16 weeks to analyze the rate of 
glucose clearance from the blood.    Mice were fasted overnight (18 hours) prior 
to GTTs by being placed in clean cages with access to water but not food.  Body 
weights were evaluated at each time point to observe changes between WT and 
E-sel KO mice.  Basal blood glucose levels were measured before and at 15, 30, 
45, 60, 90, and 120 mins post intraperitoneal injection with 1 g glucose/kg in 
PBS. No significant changes were observed in glucose tolerance between WT 
and E-sel KO animals on either normal chow or on HFD at 8, 12 or 16 weeks on 
HFD (Fig. 2.7).   
To determine whether E-sel KO mice are more insulin sensitive, plasma 
insulin levels were analyzed (Fig. 2.8).  E-sel KO and WT mice were sacrificed 
after 17-18 weeks on a NCD or a HFD, and retro-orbital plasma insulin levels 
were quantified.   Although not significant, there was a trend towards decreased 
insulin levels in E-sel KO mice on HFD. Increasing the number of animals may 
be required to reach statistical significance.  These data imply that there is a 
trend towards enhanced insulin sensitivity in E-sel KO mice. 
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To examine whether E-sel KO mice display altered expression of other 
LCAMs, we analyzed mRNA expression of Icam-1, Vcam-1 and P-sel.  WT and 
E-sel KO mice were placed on either a NCD or a HFD for 16 weeks.  GTTs were 
conducted at 16 weeks, and animals were sacrificed after 17-18 weeks on HFD.  
mRNA was extracted from whole VAT and analyzed using RT-PCR  (Fig. 2.9).  
No significant changes were observed in Icam-1 and Selp expression in WT 
versus E-sel KO mice on NCD or HFD. In contrast, Vcam-1 expression was 
increased in E-sel KO mice on HFD versus WT mice on a HFD (p=0.047, N=4-
10). 
E-sel KO mice challenged with the β3-adrenergic receptor agonist CL 
316,243 display decreased immune cell infiltration (Fig.2.5).  Therefore, we 
examined the expression of inflammatory cytokines and macrophage marker 
genes in E-sel KO mice challenged with long term HFD. VAT was extracted from 
WT and E-sel KO mice fed either NCD or HFD for 17-18 weeks (Fig. 2.10). No 
significant changes were observed in Tnf-α or Mcp-1 gene expression in E-sel 
KO mice on HFD when compared to WT controls (N=4-10). 
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Figure 2.9 Vcam-1 mRNA expression is upregulated in E-selectin KO mice 
on HFD compared to WT controls.  E-sel KO and WT mice were placed on 
either NCD or HFD for 17-18 weeks.  mRNA expression of Icam-1, Vcam-1, and 
Selp (*; p<0.05, N=4-10) in total VAT was analyzed by RT-PCR.  Gene 
expression is normalized to 36b4.   
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Next, we analyzed the expression of macrophage marker genes in total 
VAT of WT and E-sel KO mice on NCD or HFD (Fig. 2.11).   There was a 
significant decrease in Emr1 expression in E-sel KO mice on HFD when 
compared to WT mice on HFD (p=0.041, N=4-10).  In addition, mRNA levels of 
cd68, itgam, and itgax displayed a trend towards decreased expression in E-sel 
KO mice on HFD compared to WT mice.  Decreased expression of macrophage 
markers in E-sel KO mice on a HFD is consistent with the observation of reduced 
immune cell infiltration in E-sel KO mice after CL 316,243 treatment (Fig. 2.5). 
E-sel KO mice were protected from CL 316,243-induced leukocyte 
infiltration (Fig. 2.6). We next quantified the levels of myeloperoxidase (MPO), a 
peroxidase enzyme released by neutrophils during inflammation, in E-sel KO and 
WT mice that were fed NCD or HFD (Fig. 2.12).  A trend towards decreased 
MPO levels was observed in E-sel KO mice on both NCD and HFD compared 
with WT controls after 17-18 weeks. Increasing the number of animals studied 
may reveal statistical significance.  
Finally, we performed flow cytometry to identify the types of immune cells 
that infiltrated the AT.  WT and E-sel KO mice were placed on a HFD for 17-18 
weeks and then fasted for 24 hours before analysis.  The immune cell content of 
the SVF isolated from the VAT was analyzed.  There was a 22% decrease in 
macrophage infiltration (p=0.010) as marked by a decrease in F4/80 and CD11b 
positive cells in E-sel KO mice compared to the WT controls (Fig. 2.13).  
However, no significant changes were observed in the CD11b+, F480+ and 
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CD11c+ cell population, which are thought to be the pro-inflammatory 
macrophages, when comparing E-sel KO mice to the WT controls.  These results 
are consistent with the finding that E-sel KO mice are protected from immune cell 
infiltration upon CL-316,243 treatment (Figs. 2.5 B and 2.6 A).  Following acute 
treatment of E-sel KO and WT mice with CL 316,243, there was a significant 
decrease in neutrophil infiltration in E-sel KO mice (Figs. 2.6 B-D).  In contrast, 
long term (17-18 weeks) HFD feeding led to increased macrophage but not 
neutrophil content in the SVF of VAT in control mice, possibly because over time 
neutrophils are replaced by macrophages, the more chronic inflammatory 
immune cell type.  Cellular content was not addressed at this point, which may 
be different in the E-sel KO animals compared to WT on a HFD. 
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Figure 2.11 Decreased gene expression of macrophage markers in E-
selectin KO mice on HFD.  E-sel KO and WT mice were placed on a NCD or 
HFD for 17-18 weeks.  VAT was extracted, and mRNA expression was analyzed 
via RT-PCR for the indicated genes.  There is a significant decrease in Emr1 
mRNA expression in E-sel KO mice (*;p=0.041, N=4-10). 
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Figure 2.13 E-selectin KO mouse AT has reduced macrophage content after 
HFD.  E-sel KO and WT mice were placed on a HFD for 17-18 weeks.  VAT SVF 
was isolated, and FACS analysis was performed.  Upper panel (A., B.), HFD-fed 
WT animals.  Middle panels (C.,D.), HFD-fed E-sel KO animals.  Lower panels 
(E., F.), quantification of F4/80+Cd11b+ positive (*; p= p=0.010, N=6) and 
Cd11b+Cd11c+ (right) cells from WT control and E-sel KO mice. 
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Discussion 
 
Much effort has been expended in recent years to understand the immune 
response that ensues in AT in obesity. Though many hypotheses have been 
brought forth to explain why this immune response occurs, recent studies 
suggest that lipids released by AT lipolysis may mediate this response [9-10]. To 
that end, increased AT leukocyte infiltration was observed in response to either 
fasting or β-adrenergic stimuli that cause lipid release from adipocytes [9-10]. 
The findings we present here confirm that immune cell infiltration into AT occurs 
in both chemical and fasting-induced models of lipolysis. Importantly, however, 
our studies revealed that these two modes of stimulation initiate quite different 
immune responses.  
First, whereas CL 316,243-mediated inflammation is associated with 
neutrophil recruitment (Fig. 2.1), fasting-mediated inflammation is associated with 
macrophage accumulation (Fig. 2.4). These data are in contrast to a previous 
report that suggested that the infiltrating cells in both scenarios were 
macrophages [9]. The differences between our studies could be attributed to 
differences in methodology; for example we used only 0.5-1 mg/kg of CL 316,243 
as compared to the 2 mg/kg of CL 316,243 used by their group.  Second, CL 
316,243-mediated inflammation is associated with acute increases in 
inflammatory cytokines (Figs. 2.2, 2.6), while fasting-induced inflammation is 
associated with decreases in these same cytokines (Fig. 2.4). Third, and most 
strikingly, the CL 316,243-mediated immune response is associated with 
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increased adipose-resident EC LCAM up-regulation, and requires E-sel (Figs. 
2.3, 2.5, 2.6). Conversely, fasting-induced inflammation did not cause adhesion 
molecule up-regulation, and did not require E-sel (Fig. 2.4). Thus, the data 
presented herein suggest that though lipolysis triggers AT immune cell infiltration, 
there must be other factors in addition to lipolysis that determines what type of 
inflammation will ensue.  
In immune responses, there is an ordered pattern to leukocyte rolling 
within the blood vessel and transmigration into inflamed tissues [12]. Indeed, 
leukocyte rolling velocity is decreased in AT from obese mice [14]. Furthermore, 
recent studies have suggested that AT inflammation in obesity is mediated by 
leukocyte recruitment from the blood [36]. LCAMs E- and P- sel mediate 
neutrophil rolling along blood vessels [11, 12], which slows down the leukocytes 
and allows them to firmly adhere, a process mediated by ICAM-1. Finally the 
cells can leave the vessel through integrin-mediated interactions [11, 12, 37].  
Though E- and P-sel have been shown in many contexts to have 
overlapping functions [32, 33, 38, 39], the experiments described here clearly 
show that E-sel, but not P-sel, is required for CL 316,243-induced adipose tissue 
neutrophil infiltration (Figs. 2.5, 2.6). This is also supported by the fact that 
among the LCAMs that were up-regulated after β3-adrenergic receptor 
stimulation in AT, E-sel expression was increased in an acute manner and to the 
greatest extent (Fig. 2.3). Two groups recently demonstrated that P-sel-mediated 
interactions are necessary for obesity-induced IR and glucose intolerance [15, 
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16]. However, no studies have been performed to determine whether E-sel plays 
a role in this process.  
It was recently shown that adrenergic impulses activate ECs in the bone 
marrow and skeletal muscle, and that these impulses were necessary for 
circadian oscillations that govern basal leukocyte recruitment to peripheral 
tissues [40]. The data presented here also suggest that β-adrenergic stimuli 
activate adipose-resident endothelium; thus, basal AT inflammation, particularly 
neutrophil infiltration, may have a circadian pattern. Little is known about 
neutrophil function in AT; however, recent studies suggest that these cells may 
have a pro-inflammatory function and contribute to tissue dysfunction in obesity 
[22, 26, 41]. Because E-sel null animals are protected from neutrophil infiltration 
in response to CL 316,243 administration (Figs. 2.5, 2.6).  To test whether E-sel 
null animals may be protected from HFD-induced neutrophil infiltration, we 
placed WT and E-sel KO animals on HFD.  However, we did not observe 
changes in neutrophil content in the E-sel KO animals compared to WT at the 
tested time points.   
As long-term, low-dose CL 316,243-treatment is associated with improved 
glucose tolerance and insulin sensitivity [42, 43], it is difficult to envision how 
neutrophil infiltration, which is pro-inflammatory, may be associated with the 
beneficial phenotypes of CL 316,243-treatment. We suggest that perhaps chronic 
adrenergic stimulation, as with therapeutic CL 316,243-infusion, promotes a 
desensitized state in which no further activation can occur. Indeed, the 
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endothelium enters a period that is refractory to activation after a prior stimulation 
to control excessive inflammation [44].  
There are several possible reasons why CL 316,243 treatment but not 
fasting activates adipose-resident endothelium (Figs. 2.3, 2.4). First, different 
lipid species may be released by chemically induced β3-adrenergic receptor 
stimulation and fasting that may affect the endothelium differently. Several 
observations suggest that fatty acids released from adipocytes contribute to this 
phenomenon. ATGL-deficient mice are resistant to fasting-induced macrophage 
infiltration (9) and HSL-deficient mice are resistant to CL 316,243-mediated CCL-
2/MCP-1 up-regulation [17], suggesting that lipolysis is necessary for inducing 
inflammation in both systems. However, mice lacking HSL have increased basal 
AT inflammation in the context of reduced lipolysis [17], further supporting the 
idea that other factors also contribute to AT inflammation.  
Second, fasting is associated with hormonal changes such as reduced 
leptin secretion [45], which may modulate pathways that are dominant over 
lipolysis-driven signaling mechanisms. Finally, CL 316,243 treatment of mice, 
shown here to be associated with elevated AT inflammatory cytokine levels (Figs. 
2.2, 2.3), was also reported to greatly increase serum insulin levels [46, 47] in a 
manner that is dependent on β3-adrenergic receptor expression in WAT [47]. At 
high concentrations, insulin can stimulate expression of adhesion molecules on 
the endothelium and promote leukocyte adhesion [48, 49]. Therefore, elevated 
cytokine or insulin levels may act alone or synergistically to activate the 
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endothelium. This hypothesis may explain why incubation of HUVECs with CL 
316,243 alone had no effect on adhesion molecule expression (Fig. 2.3). 
Furthermore, AT inflammatory responses to CL 316,243 versus fasting may differ 
in part because fasting stimulates lipolysis more slowly and without the rise in 
insulin levels observed upon CL 316,243 treatment.  
Taken together, these results suggest that the immune response in AT is 
complex and likely is stimulus-specific. Furthermore, different stimuli may enact 
distinct patterns of EC activation that enable infiltration by specific populations of 
immune cells. The data presented herein suggest that lipolysis in and of itself is 
not sufficient to induce AT immune cell infiltration, because fasting and CL 
316,243-treatment induced lipolysis to a similar extent, as measured by plasma 
NEFA levels, yet induced very different inflammatory responses. Thus, there are 
additional factors that not only contribute to inflammation, but also contribute to 
the type of inflammation that occurs. Finally, for these reasons it is inappropriate 
to use CL 316,243-treatment and fasting interchangeably as a means to study 
acute AT inflammation. It will be important to determine the mechanistic 
differences in inflammatory responses under these various physiological 
conditions to fully understand their functional roles in adipose biology and 
systemic glucose tolerance.  
As E-sel KO mice were protected from immune cell infiltration, we 
expected similar results upon a challenge with a long term HFD.  After 16 weeks 
on a HFD, we did not detect any significant changes in glucose tolerance of E-sel 
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KO mice compared to WT controls, as there were no changes in GTT or plasma 
insulin values (Figs. 2.7, 2.8).  Of the macrophage markers analyzed, we 
identified a significant decrease in the expression of Emr1 (Fig. 2.11). There was 
also a significant decrease in F4/80+Cd11b+ cells within the VAT SVF of E-sel 
KO mice compared to WT controls as assessed by flow cytometry (Fig. 2.13).  
Taken together, these data suggest a trend towards decreased leukocyte 
infiltration in E-sel KO mice on a HFD.  However, we did not detect protection 
against obesity-induced glucose intolerance.  Perhaps increasing the number of 
animals in the study would help elucidate the potential role of E-selectin in HFD-
diet-induced AT inflammation and consequent insulin resistance. 
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Abstract 
 
Signaling pathways that control EC permeability and leukocyte adhesion 
are pivotal for the initiation and progression of atherosclerosis [1, 2]. Recently, 
the ste-20-like MAP4K4 was identified as a mediator of EC permeability in vitro 
[3], thus suggesting a potential role for MAP4K4 in atherosclerosis progression in 
vivo. Here, we demonstrate by gene silencing and gene ablation that endothelial 
MAP4K4 promotes Western diet-induced aortic macrophage accumulation and 
atherosclerotic plaque development in mice. Inducible KO of MAP4K4 in ECs of 
Apoe-/- mice dramatically reduced atherosclerotic lesion area as assessed by Oil 
red-O staining. Furthermore, loss of EC MAP4K4 in Apoe-/- mice strongly 
attenuated macrophage content and homing of injected GFP-labeled 
macrophages into atherosclerotic plaques. MAP4K4 silencing in cultured ECs 
also attenuated cell surface adhesion molecule expression while reducing 
nuclear localization and activity of NFκB, which is critical for promoting EC 
activation and atherosclerosis. Taken together, these results reveal that MAP4K4 
is a key signaling node and therapeutic target that promotes vascular 
inflammation and immune cell recruitment in atherosclerosis.  
 
 
 
 
CHAPTER III 107 
 
 
Introduction 
 
 
Atherosclerosis is an inflammatory disease that is initiated by oxidized 
lipoprotein-mediated vascular inflammation, which enhances cytokine secretion 
and endothelial LCAM upregulation to promote monocyte extravasation from 
blood vessels into the sub-endothelial space, where they accumulate as foam 
cells and proliferate locally [1, 2, 4]. Excess expression of cell surface adhesion 
molecules, particularly VCAM-1, initiates pro-inflammatory events and has been 
implicated in atherosclerotic lesion initiation and progression [5-9].  This series of 
dysfunctions contributes to cardiovascular events such as myocardial infarct, 
ischemia and stroke, which are leading causes of death [1, 2].  
MAP4K4 can function as a pro-inflammatory mediator and promotes the 
effects of TNF-α in multiple cell types [10-12]. We observed that MAP4K4 was 
highly expressed in HUVECs; thus, we hypothesized that MAP4K4 might also 
promote the inflammatory functions of the endothelium. Original reports 
demonstrated a role for MAP4K4 upstream of the JNK signaling cascade as a 
MAP4K [13-15]. In ECs, both JNK and NF-κB signaling cascades become 
activated in response to cytokines, which converge to regulate the expression of 
several inflammatory genes including those encoding LCAMs [16]. Furthermore, 
inhibiting upstream signaling cascades that promote adhesion molecule 
expression such as NF-κB specifically in ECs ameliorates atherosclerosis 
progression [17]. Recent reports also suggest that MAP4K4 enhances 
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endothelial permeability, which contributes to vascular inflammation and 
atherosclerosis [3]. Thus, we hypothesized that MAP4K4 might promote 
inflammation in the endothelium as well as diseases that are mediated by 
vascular inflammation such as atherosclerosis.   
Here, we present multiple points of evidence that endothelial MAP4K4 
profoundly influences atherosclerotic development in hyperlipidemic mice. 
Reduction or loss of endothelial MAP4K4 expression ameliorated atherosclerotic 
lesion development in mice, which was accompanied by reduced aortic 
macrophage content and compromised leukocyte homing to atherosclerotic 
plaques. Using human ECs, we determined that endothelial MAP4K4 depletion 
lessened the inflammatory capacity of the endothelium by reducing TNF-α-
mediated permeability, leukocyte adhesion, and LCAM expression.  Thus, the 
data presented here suggest a major role for MAP4K4 in promoting vascular 
inflammation and atherosclerosis. 
The mechanism by which MAP4K4 mediates these processes remains 
unclear. Here we present data to suggest that MAP4K4 may function by 
regulating NF-κB mediated target gene transcription. However, additional 
pathways may also be involved downstream of MAP4K4. A recent study 
identified an interaction between MAP4K4 and LATs, a component of the Hippo 
signaling pathway [18].  This exciting find provides additional insight into the 
function of MAP4K4. Indeed, we observed that MAP4K4 depletion in HUVECs 
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leads to reduced LATS phosphorylation suggesting this interaction may be 
required for certain functions of ECs. However, whether this interaction plays a 
role in the development of atherosclerosis remains to be determined.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER III 110 
 
 
Experimental Procedures 
 
Generation of mice 
A U6-based vector was used for transgenic mouse generation according 
to the method by Ventura et al., PNAS, 2004 [19]. MAP4K4-pSico mice were first 
crossed to Ve Cadherin-Cre transgenic mice (B6.Cg-Tg(Cdh5-cre)7Mlia/J, 
Jackson Laboratories), and these animals were then crossed onto the ApoE-/- 
background (B6.129P2-Apoetm1Unc/J, Jackson Laboratories). ApoE genotyping 
was performed according to the method of Jackson Laboratories. Map4k4 
flox/flox animals were crossed to a tamoxifen-inducible endothelial-specific Cre 
mouse line (Cdh5(PAC)-CreERT2) that was obtained from Dr. Ralf Adams [20], 
and these animals were crossed onto the ApoE-/- background as above.  
The original pSico-MAP4K4 lentiviral vector [19] was modified by cleavage 
to remove viral elements (5' SIN-LTR, HIV-RRE, flap and 3' SIN-LTR), which left 
only the U6 promoter, first loxP site, CMV-EGFP cassette, second loxP site, 
MAP4K4 shRNA coding region, and Woodchuck hepatitis virus 
posttranscriptional Regulatory Element (WRE). To create a conditional U6 
promoter, a cytomegalovirus (CMV)-enhanced stop cassette was inserted 
between two loxP sites (Fig. 3.1A). A functional U6 promoter is generated after 
cre excision, which drives expression of a hairpin targeting MAP4K4 
(GCTGTCTGGTGAAGAATTA). Because the polyadenylation site is necessary 
for EGFP expression is in the 3' SIN-LTR, we were able to preclude any 
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possibility of EGFP expression in primary tissues and thus any side effects of 
EGFP expression. The U6 promoter still produced MAP4K4 siRNA transcripts 
because the 6-nucleotide polyT sequence at the end of the MAP4K4 shRNA 
antisense sequence is recognized as a termination signal by RNA pol III 
promoters including U6. The construct was injected into eggs at the 1-cell stage, 
and 2-cell stage eggs were implanted into pseudo-pregnant C57Bl/6J females by 
the UMASS transgenic animal facility. The animals were then backcrossed onto 
C57Bl6/J mice for 7 generations. Genomic DNA was extracted from the obtained 
mice and subjected to PCR for genotyping (shRNA primer 5’-
CCCGTATGGCTTTCATTTTCTCC-3’, 5’-AAGGAAGGTCCGCTGGATTGAG-3’). 
Cre and ApoE genotyping was performed according to the protocols outlined by 
Jackson Laboratories. MAP4K4 flox/flox animals were obtained from the Texas 
A&M Institute for genomic medicine. Animals were backcrossed to BL6/J mice for 
7 generations prior to crossing them to the Cdh5(PAC)-CreERT2 mouse line. 
 
Atherosclerosis models 
At 6-8 weeks of age, male flox/flox and flox/flox/cre+ littermates were 
injected with 1 mg tamoxifen/day in corn oil (Sigma) for 5 days. At 5-6 weeks of 
age (KD mice) or 2 weeks after tamoxifen injection (flox mice), the mice were fed 
chow or Western diet (0.2% cholesterol, TD 88137, Harlan laboratories) for 16 
weeks.  Mice were euthanized by CO2 inhalation followed by bilateral 
pneumothoracotomy. No statistical methods were used to predict sample size, no 
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randomization was performed, and the investigations were not blinded during the 
KO animal analyses. The University of Massachusetts Medical School 
Institutional Animal Care and Use Committee approved all of the animal 
procedures. 
Primary endothelial cell isolation 
Lungs were excised, minced, and digested in 0.1% collagenase (Sigma) in 
RPMI (Life Technologies) for 1 hour.  Digested cells were filtered, spun, and 
plated in pre-isolation media consisting of 20% heat-inactivated FBS, 40% F-12 
HAM media, 40% GlutaMAX media, 2x L-glutamine, 1x penicillin/streptomycin 
(Life Technologies), 0.1 mg/mL heparin (Sigma), 1x endothelial cell growth 
supplement (BD).  When confluent, cells were magnetically selected with anti-rat 
dynal beads (Life Technologies) that had been conjugated to anti-CD31 and anti-
CD102 antibodies (BD). Selected cells were grown in Endothelial Cell Growth 
Medium, EGM2-MV (Lonza), 15% FBS and 2x L-glutamine until confluent. 
Unselected cells were kept as the non-endothelial cell fraction as a positive 
control. 
Cell culture and transfection 
HUVECs (purchased from Clonetics, mycoplasma negative) were 
maintained in EGM-2 media (Lonza) at 37°C and 5% CO2.  Scrambled 
(GACCAACUCUGGCUUGUUA) or MAP4K4 (CAGUCGCGUUUGCGACUGG) 
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siRNA (25 nM, Dharmacon) was reverse transfected with RNAiMax (Life 
Technologies) for 48 h prior to experiments.  
THP-1 Adhesion 
 HUVECs were transfected with scrambled or MAP4K4 siRNA as above. 
THP-1 monocytes were cultured in RPMI media and fluorescently labeled with 
calcein-AM (BD) according to the package insert 30 minutes prior to the 
adhesion assay. HUVECs were stimulated with 10 ng/mL TNF-α (Calbiochem) 
for 3-6 hours. In total, 1 x 10^6 THP-1 cells were incubated with the activated 
HUVECs for 30 minutes at 37ºC.  Non-adherent THP-1 cells were washed away, 
the cells were fixed, and the remaining cells were imaged with fluorescence 
microscopy at 488 nm. At least five random fields were quantified per condition 
as the average number of adherent cells per field. 
Endothelial permeability 
The In Vitro Vascular Permeability Assay Kit (Millipore) was used 
according to the manufacturer’s instructions. After the cells reached confluence, 
they were treated overnight with 10 ng/mL TNF-α or left untreated.  
RNA isolation and quantitative RT-PCR 
 Total RNA was isolated following the manufacturer’s protocol (TriPure, 
Roche).  Precipitated RNA was treated with DNAse (DNA-free, Life 
Technologies) prior to reverse transcription (iScript Reverse transcriptase, 
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BioRad).  SYBR green quantitative PCR (iQ SYBR green supermix, BioRad) was 
performed on the BioRad CFX97.  Primer sequences are as follows: MAP4K4 
(hum): 5’- GGGGAACGCTTCAGAGTGAG-3’, 3’- GTGCGGTCAGATCAGCAGG-5’; 
ICAM-1 (hum): 5’- TCTGTGTCCCCCTCAAAAGTC-3’, 3’- 
GGGGTCTCTATGCCCAACAA-5’; VCAM-1 (hum): 5’- ATGCCTGGGAAGATGGTCG-3’, 
3’- GACGGAGTCACCAATCTGAGC-5’; SELE (hum): 5’- 
GATGAGAGGTGCAGCAAGAAG-3’, 3’- CTCACACTTGAGTCCACTGAAG-5’; RPLP0 
(hum): 5’- CAGATTGGCTACCCAACTGTT-3’, 3’- GGGAAGGTGTAATCCGTCTCC-5’; 
Map4k4: 5’- CATCTCCAGGGAAATCCTCAGG-3’, 3’- 
TTCTGTAGTCGTAAGTGGCGTCTG-5’; Icam-1: 5’- GTGATGCTCAGGTATCCATCCA-
3’, 3’- CACAGTTCTCAAAGCACAGCG-5’; Vcam-1: 5’- 
AGTTGGGGATTCGGTTGTTCT-3’, 3’- CCCCTCATTCCTTACCACCC-5’; Sele: 5’- 
ATGAAGCCAGTGCATACTGTC-3’, 3’- CGGTGAATGTTTCAGATTGGAGT-5’; Selp: 5’- 
CATCTGGTTCAGTGCTTTGATCT-3’, 3’- ACCCGTGAGTTATTCCATGAGT-5’; Emr-1: 
5’- CCCCAGTGTCCTTACAGAGTG-3’, 3’- GTGCCCAGAGTGGATGTCT-5’; Cd68: 5’- 
CCATCCTTCACGATGACACCT-3’, 3’- GGCAGGGTTATGAGTGACAGTT-5’; 36b4: 5’- 
TCCAGGCTTTGGGCATCA -3’, 3’- CTTTATCAGCTGCACATCACTCAGA-5’; VCAM-1 
(ChIP hum): 5’- TCAGCATTGTCCTTTATCTTTCCAG-3’, 3’- 
ACTATTAACCCCTTCAGTTGCTCTC-5’; SELE (ChIP hum): 5’- 
CAAGAGACAGAGTTTCTGACATCAT-3’, 3’- TTTATAGGAGGGATTGCTTCCTGTG-5’.  
Western blotting 
Cells were lysed in RIPA lysis buffer (1% NP-40, 50 mM Tris pH 7.4, 150 
mM NaCl, 0.1% SDS, 1% sodium deoxycholate, 50 mM EDTA) with 1x HALT 
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protease and phosphatase inhibitors (Thermo Scientific). Lysates were run on 
SDS-PAGE gels and transferred to nitrocellulose membranes.  Membranes were 
immunoblotted with anti- ICAM-1 BBIG-I1, VCAM-1 BBIG-V1, E-selectin BBIG-
E4 (R&D systems), MAP4K4 A301-503A (Bethyl), VE-Cadherin 2500, p-JNK1/2 
4668, total JNK 1/2 9258, p-p38 MAPK 4631, p-IκBα 9246, IκBα 4814, p-p65 
3039, p65 8242, HGK 3485, LATS1 C66B5, pLATS1 D57D3 (Cell Signaling 
Technology), total p38 MAPK sc-535 (Santa Cruz), or Lamin β1 ab16048 
(Abcam) antibodies. 
Biochemical fractionation 
The NE-PER cellular nuclear fractionation kit (Thermo Scientific) was used 
for nuclear extract preparation according to manufacturer’s instructions.  
Luciferase assay 
The NF-κB luciferase reporter plasmid was a kind gift from the Sankar 
Ghosh lab [21]. Luciferase reporter plasmids or control plasmids were 
transfected into HUVECs with the JET-PEI HUVEC transfection system 
(Polyplus). After 24 hours, cells were treated with 10 ng/mL TNF-α or left 
untreated for 24 additional hours. Luciferase and SV40 Renilla were measured 
with the dual luciferase reporter assay system (Promega) according to 
manufacturer’s instructions. 
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Chromatin Immunoprecipitation 
HUVECs were transfected as described above and either left unstimulated 
or stimulated with 1 ng/mL TNF-α for 1 hour to induce p65 nuclear localization. 
The Simplechip enzymatic chromatin IP kit (Cell Signaling Technology) was used 
according to the manufacturer’s instructions. p65 antibodies (Santa Cruz sc-312) 
were used for p65 immunoprecipitations. VCAM-1 and E-sel (SELE) primer 
sequences are listed above. IKBα primers were purchased from Cell Signaling 
technology. 
Aortic staining 
Mouse aortas were perfused with PBS followed by 10% formalin or 4% 
PFA.  Aortic root sections were embedded in OCT for frozen sectioning. Photos 
of aortic root sections were taken with an Axiovert 35 Zeiss microscope (Zeiss, 
Germany) equipped with an Axiocam CCl camera at 25x magnification. En face 
stained aortas and light microscopy was obtained with a Nikon Stereo 
microscope equipped with a Spot Insight camera (Spot Imaging) at 5x 
magnification. Aortic root sections and en face preparations were stained with oil 
red-o in 60% isopropanol or 80% methanol. Images were quantified using Image 
J or Image Pro Plus Analysis Software (Media Cybernetics). 
Leukocyte homing 
Peritoneal exudate cells were elicited by an intraperitoneal injection of 4% 
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thioglycollate into C57BL/6-Tg(UBC-GFP)30Scha/J mice (Jackson Laboratories). 
After 2 days, 3 million cells were injected i.v. into control or MAP4K4 KD mice 
that had been fed a Western diet for 16 weeks. After 2 days, aortic arches were 
embedded in OCT. Total fluorescent cells were counted in 10x 8 um sections 
over a 0.5 mm area, and the cell number was normalized to plaque area.   
Statistical Analysis 
A two-tailed Student’s t-test was used to compare two groups in Microsoft 
Excel. Where indicated, experiments comparing multiple groups were analyzed 
with one-way ANOVA and Bonferroni post-test in Graph Pad Prism 6.0. P <0.05 
was considered to be statistically significant. Variance was estimated using the 
standard error of the mean. 
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Results 
 
 
Map4k4 KD Animals have Reduced Atherosclerotic Plaques compared to 
WT while on Western Diet 
Mice lacking MAP4K4 display embryonic lethality [22]. Thus, to assess 
whether endothelial MAP4K4 contributes to atherosclerosis development, a 
model of shRNA-mediated endothelial-specific MAP4K4 silencing was generated 
[19]. In this mouse model, constitutively expressed Cre recombinase expression 
under control of the VE-cadherin promoter drives U6 promoter recombination and 
tissue-specific shRNA expression (Fig. 3.1A). Mouse lung endothelial cells 
(MLECs) from MAP4K4shRNA-VE-Cadherin Cre-expressing mice (MAP4K4 KD) 
demonstrated a significant reduction in MAP4K4 mRNA and protein expression 
compared with the MAP4K4shRNA mice that did not express Cre (controls, Fig. 
3.1B-C). MAP4K4 KD mice were crossed onto Apoe-/- animals, and 
atherosclerotic lesion size was assessed after Western diet (WD) feeding. 
MAP4K4 KD animals displayed a significant 31% reduction in aortic root lesion 
area (Fig. 3.1D-E) and a 50% reduction in en face prepared aortic lesion areas 
as assessed by Oil red-O staining compared with controls (Fig. 3.1F-G). 
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Figure 3.1. Reduced atherosclerosis in mice upon partial silencing of 
endothelial MAP4K4 expression. A.  Schematic of the transgenic construct 
used to generate MAP4K4 KD animals. The U6 promoter becomes reconstituted 
after Cre-mediated recombination to drive tissue-specific shRNA expression. (B-
C) Primary lung endothelial cells (MLECs) were derived from control and 
MAP4K4 KD animals. B. mRNA was extracted and quantitative RT-PCR was 
performed for Map4k4 in immune-selected or unselected cells. The data 
represent the mean ± SEM as normalized to 36b4 expression (*; p<0.05, N=7) C. 
Primary endothelial or unselected cell lysates were immunoblotted for Map4k4 
and Vegfr2. Data represent the mean ± SEM as normalized to tubulin expression 
(*; p<0.05, N=3-6).  
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Figure 3.1 Continued. Reduced atherosclerosis in mice upon partial 
silencing of endothelial MAP4K4 expression. (D-G) shRNA cre transgenic 
mice with MAP4K4 KD were crossed to Apoe-/- mice and fed a WD for 16 weeks. 
D. Aortic root sections of control and MAP4K4 KD animals stained with Oil red-O. 
E. Quantification of aortic root lesion area. Data represent the mean ± SEM (**; 
p<0.005, N=6-8). F. Oil red-O stained en face aortic preparations from control 
and MAP4K4 KD animals. G. Quantification of Oil red-O-stained area. Data 
represent the mean ± SEM (*; p<0.05, N=5-7).  
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Constitutively expressed VE-Cadherin Cre can express in the 
hemangioblast during development [23-25]. Because MAP4K4 is an 
inflammatory regulator in macrophages [10], deletion in bone marrow-derived 
cells during development could confound the interpretation of the MAP4K4 KD 
animals. Thus, we additionally generated endothelial-specific MAP4K4 KO mice 
by crossing MAP4K4 flox/flox animals to tamoxifen-inducible VE-Cadherin Cre 
mice [24] (Fig. 3.2A). At 6-8 weeks of age, MAP4K4 flox/flox or MAP4K4 flox/flox 
Cre+ (MAP4K4 ECKO) animals were injected with tamoxifen (Fig. 3.2B). 
Immune-selected MLECs derived from MAP4K4 ECKO animals displayed 
markedly reduced MAP4K4 mRNA and protein expression, whereas cells that 
were not immune-selected displayed no reduction (Fig 3.2C-D). Furthermore, 
MAP4K4 levels were unaltered in whole blood leukocytes from these animals, 
confirming endothelial specificity (Fig. 3.2D). 
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Figure 3.2. Reduced atherosclerosis in a mouse model of inducible 
endothelial MAP4K4 deletion. Map4k4 flox/flox animals were crossed to 
Cdh5(PAC)-ERT2-Cre animals and injected with tamoxifen for 5 consecutive 
days at 6-8 weeks of age. A. Cre-mediated Map4k4 exon 7 deletion. B. 
Schematic of injection and feeding scheme. C. mRNA was extracted and qRT-
PCR was performed for Map4k4 in primary MLECs, the unselected, non-EC 
fraction of mouse lung cells, and peripheral blood leukocytes. The data represent 
the mean ± SEM as normalized to 36b4 expression (*; p<0.05, N=6-8). D. 
Immunoblots were performed for MAP4K4 or tubulin in immune-selected primary 
MLECs and the un-selected, non-EC fraction of mouse lung cells. Western blots 
are representative of 6-8 animals per group. 
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Map4k4 KO Animals have Reduced Atherosclerotic Plaques compared to 
WT while on Western Diet 
MAP4K4 ECKO animals were then crossed to mice on the Apoe-/- 
background and fed WD after tamoxifen administration as in Fig. 3.2B. MAP4K4 
ECKO animals also demonstrated a 66% reduction in lesion area at the aortic 
root (Fig. 3.2E-F), and en face preparations revealed that the Oil red-O stained 
area was also reduced by 58% after WD (Fig. 3.2G-H), confirming the results 
obtained from MAP4K4 KD animals. Thus, using both constitutive MAP4K4 
silencing and conditional MAP4K4 ablation approaches in mouse genetic 
models, we demonstrate that endothelial MAP4K4 expression is required for full 
atherosclerotic lesion development and progression.   
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Figure 3.2 Continued. Reduced atherosclerosis in a mouse model of 
inducible endothelial MAP4K4 deletion. (E-H) Flox/flox and MAP4K4 ECKO 
mice were crossed to Apoe-/- mice and fed a WD for 16 weeks as in B. E. Aortic 
root sections of flox/flox and MAP4K4 ECKO animals stained with Oil red-O. F. 
Quantification of aortic root lesion area. Data represent the mean ± SEM (#; 
p<0.0005, N=5-6). G. Oil Red-O stained en face aortic preparations from flox/flox 
and MAP4K4 ECKO animals. H. Quantification of Oil Red-O-stained area. Data 
represent the mean ± SEM (#; p<0.0005, N=5-6).  
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Endothelial MAP4K4 is required for Leukocyte Homing to Atherosclerotic 
Plaques 
We hypothesized that the protection from atherosclerosis observed in 
MAP4K4 ECKO and MAP4K4 KD animals was due to impaired leukocyte 
recruitment through the endothelial cell barrier and accumulation within the 
atherosclerotic plaque. Thus, aortas from control and MAP4K4 ECKO or 
MAP4K4 KD mice were isolated, and macrophage gene expression was 
estimated by qRT-PCR. Macrophage marker genes Emr1 and Cd68 were 
significantly reduced in both MAP4K4 KD and MAP4K4 ECKO mice compared 
with their respective controls (Fig. 3.3A-B). To formally determine whether 
endothelial MAP4K4 promoted leukocyte recruitment, thioglycollate-elicited 
peritoneal exudate cells were extracted from GFP-expressing mice and injected 
intravenously into control or MAP4K4 KD animals, and GFP-positive cell content 
was quantified within the aortic arch to assess homing (Fig. 3.3C). MAP4K4 KD 
mice displayed a 67% reduction in GFP-positive cell content within 
atherosclerotic plaques (Fig. 3.3D). Thus, endothelial MAP4K4 plays an essential 
role in leukocyte homing to and accumulation within atherosclerotic plaques. 
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Figure 3.3. Reduced macrophage homing and content in plaques from mice 
lacking endothelial MAP4K4. (A-B) mRNA was prepared from whole aortas, 
and qPCR was performed for macrophage markers Emr1 and Cd68. A. Control 
and MAP4K4 KD mice. Data represent the mean ± SEM as normalized to 36b4 
(*; p<0.05, 16w N=4-7). B. Flox/Flox and MAP4K4 ECKO mice. Data represent 
the mean ± SEM as normalized to 36b4 (*; p<0.05, N=8-12). (C-D) Homing of 
GFP leukocytes into atherosclerotic lesions 48 hr after intravenous injection into 
control or MAP4K4 KD mice that were fed WD for 16 weeks. C. Fluorescence 
micrograph of atherosclerotic plaque demonstrating 4 GFP leukocytes within the 
aortic arch. Dashed line indicates plaque border. Inset, magnification of 3 GFP 
leukocytes. Left, DAPI; middle, GFP; right, merge. D. Quantification of GFP 
leukocytes per square millimeter of plaque. Data represent the mean ± SEM (**; 
p<0.005, N=4,7). 
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MAP4K4 is Required for Endothelial Permeability and Monocyte Adhesion 
in HUVECs  
The significant reduction in atherosclerosis was observed in MAP4K4-
depleted mice suggested that endothelial MAP4K4 was a potent regulator of 
vascular inflammation. Thus, we assessed whether MAP4K4 was required for 
TNFα-mediated inflammation of the endothelium, including tight junction 
permeability, which allows for plasma protein leakage into inflamed tissues [26] 
and inflammatory cell adhesion to activated endothelium.  For these experiments, 
we employed HUVECs as a standard model for such analysis. Using transwell 
chambers, it was observed that TNFα induced a 65% increase in FITC-labeled 
dextran movement across a monolayer in scrambled siRNA-transfected 
HUVECs, whereas permeability was 87% and 59% reduced in MAP4K4-silenced 
HUVECs, basally and after stimulation, respectively (Fig. 3.4A). MAP4K4 also 
promoted firm monocyte adhesion to an activated endothelial monolayer. Though 
TNF-α treatment increased monocyte adhesion to scrambled siRNA-transfected 
HUVECs by 65%, both basal and stimulated monocyte adhesion to the 
endothelium was reduced by 31% and 37%, respectively, after MAP4K4 
silencing (Fig. 3.4B).  
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Figure 3.4. Endothelial MAP4K4 promotes EC adhesion molecule 
expression and permeability. HUVECs were treated with scrambled or 
MAP4K4 siRNA, and cells were stimulated with 1 or 10 ng/mL TNFα for the 
indicated times. A. Cells were seeded onto transwell chambers. Confluent cells 
were treated overnight with 10 ng/mL TNFα or left untreated, and FITC labeled 
dextran that migrated through the HUVEC monolayer was measured. The data 
represent the mean fluorescence intensity ± SEM (ANOVA *; p<0.05, N=4). B. 
THP-1 monocytes were stained with calcein green and adhered to activated 
endothelium for 30 min. Fluorescence microscopy was performed to determine 
the number of adherent THP-1 monocytes per microscopic field (100x). The data 
represent the mean ± SEM as normalized to the unstimulated control timepoint 
(ANOVA **; p<0.01, ****; p<0.0001, N=5). 
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 MAP4K4 Causes Leukocyte Adhesion Molecule Upregulation in HUVECs 
 
Because MAP4K4 promoted leukocyte adhesion to HUVECs, we 
assessed whether MAP4K4 was required for TNFα-induced cell surface 
adhesion molecule upregulation. Upon MAP4K4 silencing with siRNA, ICAM-1, 
VCAM-1, and E-sel mRNA and protein expression was blunted compared with 
scrambled siRNA-transfected cells at multiple time points (Fig. 3.4C-H, Fig. 3.5A-
D). MLECs from MAP4K4 KD mice also displayed attenuated TNF-α-induced 
LCAM expression compared with those from controls (Fig. 3.5E-H). These data 
indicate that MAP4K4 plays a cell autonomous and conserved role among 
species to regulate TNF-α-induced LCAM expression.  
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Figure 3.4 Continued. Endothelial MAP4K4 promotes EC adhesion 
molecule expression and permeability.  HUVECs were treated with scrambled 
or MAP4K4 siRNA, and cells were stimulated with 1 or 10 ng/mL TNFα for the 
indicated times. (C-F) mRNA was extracted and quantitative RT-PCR was 
performed for C. MAP4K4, D. ICAM-1, E. VCAM-1, F. SELE. The data represent 
the mean ± SEM as normalized to RPLP0 (*; p<0.05, **; p<0.005, N=5-7). G. 
Immunoblots were performed for ICAM-1, VCAM-1 and E-selectin. H. 
Densitometric analyses from G. The data represent the means ± SEM as 
normalized to VE Cadherin (*; p<0.05, N=4-6). 
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Figure 3.5. Reduced LCAM expression after MAP4K4 silencing. A-D. 
HUVECs were treated with scrambled or MAP4K4 siRNA and stimulated with 10 
ng/mL TNF-α for 24h. RNA was extracted, and qPCR was performed for A. 
MAP4K4, B. ICAM-1, C. VCAM-1, D. SELE. The data represent the mean ± SEM 
as normalized to RPLP0 (*; p<0.05, **; p<0.005, N=5-7). Primary MLECs were 
stimulated with 10 ng/mL TNF-α for 6h or left unstimulated, RNA was extracted, 
and qPCR was performed. E. Icam-1, F. Vcam-1, G. Sele, H. Selp. Data 
represent the mean ± SEM as normalized to 36b4. (ANOVA *; p<0.05, **; 
p<0.01, N=7-9). 
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No Requirement for Endogenous MAP4K4 in TNF-α-induced JNK Activation 
EC LCAM expression is controlled by the MAPK and NF-κB signaling 
pathways [16, 27-30]. MAP4K4 was originally reported to act upstream of the 
JNK signaling cascade [31, 32]; however, no changes in TNF-α-induced JNK or 
p38 MAPK activation were noted upon MAP4K4 depletion (Fig. 3.6A), consistent 
with recent reports demonstrating no requirement for MAP4K4 in JNK activation 
[10, 33, 34]. Because of the strong link between endothelial NF-κB and 
atherosclerosis [17, 35, 36], we thus investigated whether MAP4K4 might 
promote NF-κB activation. It is well established that p65 (Rel A) is retained in the 
cytosol by IκBα, which is phosphorylated and subsequently degraded upon 
stimulation with cytokines, thus allowing p65 nuclear translocation and target 
gene expression [37]. However, neither TNF-α-mediated IκBα phosphorylation 
nor its degradation were altered (Fig. 3.6B-E) after MAP4K4 silencing. 
Furthermore, IKK and p65 phosphorylation was also unaltered (Fig. 3.6B-C). 
However, in the basal state, total IκBα protein levels were increased in MAP4K4-
deficient HUVECs compared with control cells (Fig 3.6).  
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Figure 3.6. Endothelial MAP4K4 does not promote TNFα-induced MAPK or 
IKK activation. A-E. HUVECs were treated with scrambled or MAP4K4 siRNA 
and stimulated with 1 or 10 ng/mL TNF-α for the indicated times. A. Lysates were 
immunoblotted for MAP4K4, p-JNK, total JNK, p-p38 MAPK, total p38 MAPK, 
and VE-Cadherin. The data are representative of 4-5 independent experiments. 
B. Lysates were immunoblotted for MAP4K4, total IκBα, phospho-p65, total p65, 
phospho-IKKβ, total IKKβ, and VE-Cadherin. C. Densitometric analyses 
represent the mean ± SEM of IκBα expression at time 0 as normalized to VE-
Cadherin (**; p<0.005, N=4-10). D. HUVECs were pre-treated with MG132 prior 
to TNF-α stimulation. Lysates were immunoblotted for MAP4K4, phospho- IκBα, 
total IκBα, and VE-Cadherin. E. Densitometric analyses represent the mean ± 
SEM of phospho-IκBα expression as normalized to total IκBα (N=5). 
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MAP4K4 Enhances Nuclear NF-κB action in Endothelial Cells 
The lack of changes due to MAP4K4 depletion in TNF-α-mediated IKK or 
IκBα phosphorylation did not exclude the possibility that MAP4K4 could regulate 
nuclear p65 levels or activity. Thus, MAP4K4 or scrambled siRNA-transfected 
HUVECs were subjected to biochemical fractionation. In MAP4K4-depleted cells, 
less nuclear phospho-p65 and its heterodimeric partner p50 protein was 
observed after TNF-α stimulation compared with scrambled-transfected cells 
(Fig. 3.7I-J). These data suggested that MAP4K4 might regulate NF-κB nuclear 
retention or activity. Indeed, TNF-α-induced NF-κB transcriptional activity as 
assessed by a luciferase reporter containing NF-κB binding elements [21] was 
attenuated when MAP4K4 was silenced (Fig. 3.7K). Furthermore, using p65 
chromatin immunoprecipitation (ChIP) in HUVECs, TNF-α-induced p65 binding to 
the VCAM-1, E-sel, and IKBα promoters (Fig. 3.7L-N) was reduced in MAP4K4-
silenced cells, suggesting that MAP4K4 may regulate NF-κB target gene 
expression.  
 
 
 
  
CHAPTER III 135 
 
 
 
Figure 3.7. Endothelial MAP4K4 promotes nuclear NF-κB localization and 
activity. HUVECs were treated with scrambled or MAP4K4 siRNA, and cells 
were stimulated with 1 or 10 ng/mL TNF-α for the indicated times. A. Biochemical 
fractionations were performed, and nuclear fractions were immunoblotted for 
MAP4K4, p-p65, total p65, p50, and Lamin-β1. B. Densitometric analyses 
represent the means ± S.E.M. for the 60-minute timepoint as normalized to 
Lamin-β1 (*; p<0.05, N=3). C. NFκB-luciferase and SV40-Renilla were 
transfected into HUVECs after treatment with scrambled or MAP4K4 siRNA. 
Cells were left unstimulated or stimulated with 10 ng/mL TNF-α overnight prior to 
luciferase and Renilla measurement. The data represent the mean ± S.E.M. from 
4 independent experiments. D-F. HUVECs were transfected with MAP4K4 siRNA 
and stimulated or not with 1 ng/mL TNF-α for 1 hr. IgG, p65 and histone 
antibodies were used to immunoprecipitate chromatin and RT-PCR was used to 
amplify D. E-selectin, E. VCAM-1, and F. IκBα promoters.  The data represent 
the mean ± S.E.M. as normalized to input (*; p<0.05, N=3-4). 
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Although great progress has been made in the current study, we have yet 
to get a clear understanding of the signaling mechanism of MAP4K4.  A recent 
study identified an interaction between Msn, the Drosophila homolog of MAP4K4 
and Wrts, a component of the Hippo signaling pathway. This interaction was 
conserved in mammalian cells [18].  We observed similar results in Mouse 
Embryonic Fibroblasts (MEFs).  MEFs generated from Map4k4 loxP/UBC-
Cre/ERT2 mice were treated with either vehicle or tamoxifen to induce Map4k4 
deletion.  72 hours post-treatment, MEFs were treated with 0.5 ug/mL Latrunculin 
B (Lat B), an inhibitor of actin polymerization.  We were also eager to repeat a 
study that had looked at MAP4K4’s role within the Hippo pathway post-Lat B 
treatment.  Lat B was used as a potential new stimulus for MAP4K4, other than 
the already known cytokine TNF-α.  Lysates were collected 1 hour post Lat B 
treatment and analyzed for protein levels of pLATS, LATS, and MAP4K4.  Upon 
Lat B treatment, vehicle treated cells exhibited increased phosphorylation of 
LATS (Fig. 3.8).  In contrast, cells treated with MAP4K4 siRNA displayed 
significantly reduced levels of LATS phosphorylation, consistent with the report 
by Li et al. 2014 [18].   
We next tested whether MAP4K4 is required for LATS phosphorylation in 
ECs. HUVECs were transfected with either scrambled control or MAP4K4-
specific siRNA.  48 hours post transfection, the cells were treated with Lat B for 1 
hour, lysed, and levels of and pLATS, LATS, and MAP4K4 were analyzed by 
immunoblotting.  MAP4K4 silencing resulted in decreased phosphorylation of 
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LATS post Lat B treatment (Fig. 3.9), similar to in MEFs (3.8). Taken together, 
these data indicate that the regulation of LATS phosphorylation by MAP4K4 is 
highly conserved between mice and humans. Furthermore, these results may 
provide a novel mechanism by which endothelial MAP4K4 modulates vascular 
inflammation in atherosclerosis.  
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Figure 3.8. MAP4K4 is required for LATS phosphorylation upon Latrunculin 
B treatment.  MEFs from Map4k4 loxP/UBC-Cre/ERT2 mice were treated with 
either vehicle or tamoxifen. 72 hours post treatment, cells were incubated with 
Latrunculin B for 1 hr. Lysates were immunoblotted for pLATS, LATS, and 
MAP4K4 levels by immunoblotting.  These western blots are representative of 4 
independent experiments. 
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Figure 3.9. MAP4K4 silencing leads to reduced Latrunculin B-induced LATS 
phosphorylation in HUVECs. HUVECS were treated with either scrambled 
control (Scr) or MAP4K4-specific siRNA for 48 hours prior to incubation with Lat 
B for 1 hour. Lysates were analyzed for pLATS, LATS, and MAP4K4 levels by 
immunoblotting.  These western blots are representative of 3 independent 
experiments. 
 
 
 
 
CHAPTER III 140 
 
 
Discussion 
Atherosclerosis is an inflammatory disease that is initiated by lipid-
mediated vascular inflammation of the vessel wall, which promotes continual 
monocyte recruitment in an LCAM-dependent manner [5, 9, 38]. Strategies for 
developing therapeutics for this disease include the search for key cellular 
enzymes in ECs that promote leukocyte attachment and permeability and may 
serve as drug targets. We hypothesized that the protein kinase MAP4K4 may be 
a target candidate based on previous work suggesting it promotes pro-
inflammatory functions, and the data presented here support this hypothesis. 
Constitutive silencing of endothelial MAP4K4 or inducible endothelial-specific 
MAP4K4 deletion ameliorated atherosclerosis development in mice as measured 
by histology of the aortic root and Oil-red-O staining of the aorta (Figs. 3.1, 3.2). 
Furthermore, reduced macrophage marker mRNA expression was observed in 
aortas from Apoe-/- animals when endothelial MAP4K4 expression was 
attenuated, and leukocyte homing to atherosclerotic plaques within the aortic 
arch was also dramatically inhibited (Fig. 3.3). Together, these data strongly 
support the idea that MAP4K4 is a novel therapeutic target for the treatment of 
cardiovascular disease.  A caveat of this study is that no cre control animals were 
used to compare to the experimental MAP4K4 KO animals. 
To understand the mechanisms by which MAP4K4 promoted monocyte 
accumulation in atherosclerotic plaques, we utilized human ECs as a model 
system. In both HUVECs and human aortic ECs, MAP4K4 silencing blunted 
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basal and TNF-α-mediated endothelial permeability (Figs. 3.4, 3.5, 3.7). 
Furthermore, siRNA-mediated MAP4K4 depletion in HUVECs attenuated TNF-α-
induced leukocyte adhesion, which was accompanied by a reduction in TNF-α-
induced adhesion molecule expression. Finally, TNF-α induced less NF-κB p65 
binding to adhesion molecule promoters in MAP4K4-depleted cells, indicating 
that endothelial MAP4K4 promotes NF-κB-mediated gene expression (Fig. 3.7). 
A previous report from our laboratory demonstrated that macrophage MAP4K4 
was not upstream of the classical activation system for the NF-κB signaling 
pathway [10]; however, in the present experiments we noted that MAP4K4 
silencing reduced TNF-α-induced p65 nuclear localization and transcriptional 
activation without altering IκBα degradation (Figs. 3.6, 3.7A-B). These data 
suggest an alternative mechanism of NF-κB modulation by MAP4K4. The 
reduced transcriptional activation and promoter binding in response to MAP4K4 
depletion observed in the present study may be due to altered post-translational 
modifications of p65 or p50, such as acetylation which can control p65 activity 
and nuclear retention in a manner downstream of IκBα degradation [39]. Future 
studies will assess this possibility. 
Consistent with animal models that illustrate no requirement for JNK1 in 
atherosclerosis [40], our data illustrates that endothelial MAP4K4 does not 
appear to promote JNK activation (Fig. 3.6). Although no endothelial-specific 
JNK2 KO mice have been reported, the atherosclerosis protection mediated by 
JNK2 deletion is presumably due to enhanced macrophage lipid flux [40, 41]. 
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Furthermore, endothelial NF-κB is required for LCAM expression, 
atherosclerosis, and macrophage homing to atherosclerotic plaques [17, 34]. In 
addition to the inflammatory response, endothelial NF-κB also regulates systemic 
insulin sensitivity and even aging [36, 42].  Consistent with these results, a 
genome wide study of post-mortem human aortas revealed a correlation between 
hypermethylation of MAP4K4 and atherosclerosis [43].  
Furthermore, to better understand the mechanisms by which MAP4K4 
modulates inflammation and atherosclerosis, it is important to identify its 
substrates. A recent study reported a novel interaction between MAP4K4 and the 
Hippo signaling pathway [18].  We also observed that MAP4K4 is required for 
LATS phosphorylation in both MEFs and HUVECs (Figs. 3.8, 3.9).  Further 
experiments are required to determine whether LATS is a direct target of 
MAP4K4. Additionally, it is important to analyze the functional significance of this 
interaction in obesity-associated atherosclerosis. 
These data suggest that endothelial MAP4K4 is a novel regulator of 
vascular inflammation and endothelial activation that is required for 
atherosclerotic plaque development in mice. These data also implicate 
endothelial MAP4K4 in acute endothelial functions that are impaired by 
inflammation, such as endothelial barrier function or relaxation. Taken together, 
these data suggest that MAP4K4 may be a novel and important anti-
atherosclerosis therapeutic target.  
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Endothelial Cell Activation and Metabolic Homeostasis 
 
The role of the endothelium in metabolic pathogenesis has not been 
carefully examined.  In this work, we demonstrated that EC activation is required 
for immune cell infiltration following β3-adrenergic receptor stimulation-induced 
lipolysis with CL 316,243 (Figs. 2.1-2.3).  We also demonstrated that E-sel KO 
animals were protected from CL 316,243-induced AT inflammation (Figs. 2.5, 
2.6).  Taken together, these data suggest that EC activation and E-sel 
expression are required for AT inflammation in a model of pharmacologically-
induced lipolysis.  These studies were performed following acute CL 316,243 
treatment and provide insight into the function of ECs, and specifically E-sel, 
during enhanced lipolysis.    
In addition to inducing lipolysis, CL 316,243 treatment is associated with 
AT remodeling, which may or may not be due to enhanced lipolysis [1-3]. In the 
current study, we examined CL 315,243-induced changes under acute conditions 
[4].  Next steps in this work would be to define whether E-sel is required for the 
beneficial effect of AT remodeling following CL 316,243 treatment. For this study, 
CL316,243 will be administered to WT and E-sel KO mice in a longer time 
course, and AT morphology will be assessed. Furthermore, CL 316,243 
treatment has been associated with increased browning of WAT [3]. Therefore, 
we can examine whether a “browning” effect occurs in E-sel KO mice.  FACS 
analysis can also be utilized to identify the various cell populations present in the 
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AT as a recent report indicates that certain immune cells, such as eosinophils, 
are required for the browning of WAT [5]. These experiments will determine 
whether E-sel is required for AT remodeling. 
We also demonstrated that macrophage infiltration is reduced in E-sel KO 
mice on a HFD compared with WT controls (Figs. 2.11, 2.13).  However, there 
was no difference in glucose tolerance or insulin sensitivity between E-sel KO 
and WT mice (Figs. 2.7, 2.8).  Although inflammation was reduced as assessed 
by decreases in macrophage marker gene expression (Fig. 2.11), macrophage 
infiltration (Fig. 2.13) and total VAT MPO levels (Fig. 2.12), these changes were 
not statistically significant.  Because only a small cohort of mice was analyzed, 
expanding the number of mice would provide a more definitive answer about any 
potential changes between WT and E-sel KO mice on a long-term HFD. It would 
also be interesting to determine whether a fasting-refeeding model would cause 
AT remodeling and elucidate differences between WT and E-sel KO animals.  
When FGF-1 KO mice are fed a HFD, their AT is unable to adapt to the HFD 
challenge and they become diabetic [6]. Upon HFD removal the AT became 
necrotic [6].  Using the E-sel KO model, we could elucidate whether these mice 
are more or less adaptable to fasting-refeeding challenges. 
Alternatively, E-sel may play a role in the early stages of metabolic 
deregulation in the context of a HFD challenge.  Short term HFD is associated 
with enormous AT expansion.  In the course of our studies, we noted that WT 
mice displayed a significant increase in E-sel gene expression after 2 and 4 
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weeks on a HFD (p= 0.037 and 0.039, respectively). In addition, these mice 
exhibited increased Vcam-1 expression after 4 weeks on a HFD (p=0.042) (Fig. 
4.1).  Therefore, it would be interesting to elucidate whether E-sel KO mice are 
protected from HFD-induced inflammation following a short-term HFD challenge, 
as E-sel may be required for leukocyte infiltration during the changing AT 
dynamics.  This would be consistent with our data demonstrating reduced 
macrophage marker expression, inflammatory gene expression, and immune cell 
infiltration in AT shortly after acute CL 316,243 treatment in E-sel KO mice when 
compared with WT controls (Figs. 2.5B, 2.6A). Therefore, it will be important to 
also compare these parameters in E-sel KO and WT mice after 1, 2, or 4 weeks 
on a HFD.   
 One possibility for the lack of difference in glucose tolerance and insulin 
sensitivity in constitutive E-sel KO mice is that other factors, such as P-sel, may 
compensate for the loss of E-sel. Crossing E-sel KO animals with either P-sel KO 
or Vcam-1 KO mice to create double KO (DKO) mice may be needed to see a 
greater effect in glucose tolerance.  Alternatively, monoclonal murine antibodies 
can be used to dampen P-sel function in E-sel KO mice [7-8].  WT, single KO, 
and DKO mice can be placed on a HFD for varying periods of time and changes 
in the expression of cytokines, immune cell markers, and LCAMs quantified.  In 
addition, histological and flow cytometric analysis can be used to determine 
whether DKO mice show decreased immune cell infiltration when compared with 
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single KO or WT mice. Moreover, to assess changes in whole body metabolism, 
GTTs and insulin tolerance tests will be conducted. 
E-sel and other LCAMs within AT promote AT inflammation in obesity.  
Further examination is needed to determine whether specific LCAMs may be 
required for the dynamic changes seen in AT during obesity and may serve as 
novel targets for promoting beneficial changes in obesity-associated 
inflammation.   
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Figure 4.1 Leukocyte adhesion molecule expression is upregulated in WT 
mice on a short-term HFD.  WT mice (N=5) were placed on a HFD for 1, 2, and 
4 weeks.  mRNA expression of Icam-1, Vcam-1, Sele, and Selp in whole visceral 
AT was quantified by RT-PCR.  Gene expression is normalized to 36b4 (p= 
0.042 Vcam-1 at 4 weeks; E-sel at 2 weeks and 4 weeks p= 0.037 and 0.039, 
respectively).   
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MAP4K4 Signaling and Metabolic Homeostasis 
 Atherosclerosis is a cardiovascular disease that is associated with 
vascular inflammation, which requires increased LCAM expression on ECs 
followed by monocyte recruitment [9-11].  Although several therapeutic 
treatments are available for atherosclerosis, better understanding of the 
molecular underpinnings of disease progression may uncover novel therapeutic 
targets.  We observed that endothelial-specific deletion of MAP4K4 results in 
decreased atherosclerotic plaque development in mice (Figs. 3.1D-G, 3.2E-H), 
suggesting that MAP4K4 may be a novel target for atherosclerosis.  
Therefore, we sought to study the mechanism by which MAP4K4 induces 
the development of atherosclerosis.  We observed reduced binding of NF-κB p65 
at LCAM promoters (Fig. 3.7D-F), suggesting that EC MAP4K4 may promote NF-
κB-mediated gene expression.  Furthermore, silencing MAP4K4 decreased TNF-
α-induced p65 nuclear localization and transcriptional activation.  However, IκBα 
degradation was not altered (Figs. 3.6, 3.7A-B).  Taken together, these data 
suggest a potential post-translational change in p65 activity downstream of IκBα 
degradation that is involved in LCAM expression. 
 A recent study demonstrated that the Drosophila homolog of MAP4K4, 
Misshapen, regulates Hippo signaling.  Msn interacts with Warts (homolog of 
LATS) to inhibit Yorkie (homolog of YAP), and this interaction is conserved in 
mammals [12].  Consistent with these findings, we observed reduced 
phosphorylation of LATS in the context of MAP4K4 KD in MEFs and HUVECs 
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following Lat B treatment (Figs. 3.8, 3.9).  These data suggest that MAP4K4 may 
regulate LATS phosphorylation in mouse and human cells [12].  However, it is 
unclear whether MAP4K4 regulates LATS phosphorylation directly or indirectly.  
Further studies are required to elucidate whether LATS is a direct substrate of 
MAP4K4. 
 Recently, the Hippo pathway has been implicated in regulating vascular 
development and homeostasis.  One study reported a potential link between 
increased proliferation and decreased apoptosis of ECs, and in this case, a 
reduction in VE-cadherin expression was linked to increased YAP activation [13].  
In addition, Mst1 and Mst2 are highly expressed at the initiation site of primitive 
hematopoiesis in Xenopus embryos [14]. Furthermore, mice deficient in Mst1/2 
or YAP die at embryonic day 8.5 as a result of defective hematopoiesis [15-16].  
Future studies will address whether MAP4K4 may play a role in these processes.   
Given these findings, it is tempting to speculate that MAP4K4 may 
mediate LCAM expression through interaction with the Hippo pathway.  While the 
above studies suggest a role for the Hippo pathway in vascular development, 
many questions remain about the function of Hippo signaling in EC function. 
Further work will concentrate on determining whether MAP4K4-mediated 
phosphorylation of LATS, and therefore inhibition of YAP, is required for EC 
function.  In the absence of MAP4K4, HUVECs exhibit decreased expression of 
inflammatory genes.  Therefore, if MAP4K4 promotes inflammatory gene 
expression via its interaction with the Hippo pathway, then simultaneous 
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silencing of MAP4K4 and YAP should lead to a level of inflammatory markers 
expression that is comparable to MAP4K4-silenced cells.   Furthermore, 
MAP4K4 silencing alone or in combination with YAP will be used in conjunction 
with TNF-α treatment prior to analysis of LCAM and cytokine gene expression.  
These experiments may help determine whether the interaction between 
MAP4K4 and LATS is required for MAP4K4-mediated upregulation of 
inflammatory genes.  MAP4K4 may be a novel therapeutic target for 
atherosclerosis treatment, and defining the mechanisms by which MAP4K4 
attenuates inflammation in atherosclerosis will be a key finding. 
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